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Abstract
CK2 is a constitutively active, ubiquitously expressed and pleiotropic
serine/threonine protein kinase that is implicated in many cellular functions including
tumorigenesis. CK2 has two catalytic subunits, CK2 and CK2’, that carry out its
function in the cell. Previous studies have indicated that inhibitor-refractory mutants have
been effective in recovering residual CK2 activity, in the presence of inhibitors, when
compared to wild type CK2. Based on these observations, inhibitor-refractory mutants
were created for both CK2 and CK2’ and tested with various concentrations with two
CK2-specific inhibitors, CX-4945 and inhibitor VIII. The CK2 triple mutant
(V66A/I174A/H160D) was tested in inducible U2OS Flp-In cell lines with inhibitor VIII
and CX-4945 inhibitors and was found to recover residual CK2 activity 5-fold greater
than previously established CK2-(V66A/I174A) inhibitor-refractory mutants. Seven
novel mutations were made to CK2’ in vitro and tested with CK2 inhibitor CX-4945.
The mutants that recovered the most residual CK2 activity were introduced into stable
cell lines and tested with the same conditions as the CK2 catalytic subunit. Generation
of inhibitor-refractory mutants for both catalytic subunits of CK2 will provide insight into
the distinct functions, interactions with inhibitors and ability to recover activity of the two
catalytic subunits of CK2.

Dedications
I dedicate this thesis to my mother and father for all their support throughout this entire
process.

ii

Acknowledgements
First off, I would like to thank my supervisor Dr. David Litchfield for the
guidance moral support during my time at Western. I truly appreciate the consistency at
which you made time to speak with me whenever I had a concern or question – which
was quite often. Also, I wish to extend my gratitude to my advisory committee members,
Pat O’Donoghue and Murray Junop for their constructive criticism, helpful suggestions
and consistent good humor.
A huge thanks is in needed for Dr. Laszlo Gyenis, for helping me with just about
every aspect of my research. From guiding me through protocols to giving me
motivational speeches when the results were not working out the way I wanted. This
certainly would have been a less pleasant experience without your help. Eddy Cruise
worked with me on a number of experiments during my research. It would have been
difficult to finish some of the enormous titration experiments without your help. I would
also like to thank Stephanie Zukowski for helping to edit and format my writing as well
as providing me with insightful advice throughout my research. Sam Fess was
instrumental to the beginning of my research as he showed me a number of techniques in
the lab; his research was also the background that I needed to get my thesis started. I
would like to thank past and present lab members: Adam Rabalski, Teresa Diaz, Shabaz
Khan, James Plaetzer, Viviana Aguayo, Michelle Gabriel and Michelle Dubinsky for
always being open to aiding me in experimentation and providing me with advice
whenever I asked.
Finally, I would like to thank my parents for their love and support on matters
extending beyond the scope of this thesis.

iii

Table of Contents
Abstract…………………………………………………………………………………. ii
Dedications………………………………………………………………………………iii
Acknowledgements……………………………………………………………………...iv
Table of Contents……………………………………………………………………...v-vi
List of Figures…………………………………………………………………………..vii
List of Tables…………………………………………………………………………...viii
Abbreviations………………………………………………………………………….ix-x
1 – Introduction…………………………………………………………………………..1
1.1 – Protein kinases………………………………………………………………1
1.2 – Protein kinase CK2………………………………………………………….2
1.2.1 – Structure…………………………………………………………3
1.2.2 – Regulation……………………………………………………….5
1.3 – CK2 in cancer……………………………………………………………….6
1.3.1 – CK2 in tumorigenesis………………….………………………..6
1.3.2 – CK2 and tumor suppressors……………………………………..7
1.3.3 – CK2 and oncogenes……………………………………………..7
1.3.4 – CK2 in apoptosis………………………………………………...8
1.4 – Inhibition……………………………………………..……………………...9
1.4.1 – kinase inhibitors…………………………………………………9
1.4.2 – CK2 Inhibition…………….…………………………………...10
1.4.3 –CK2 inhibitors: CX-4945 and inhibitor VII…………………….11
1.5 – CK2 inhibitor-refractory
mutants…………………………………………………………………….…15
1.6 - CK2 and CK2’………………….…………………………………...….19
1.7 – Objective. ……………………………………………………………….…22
2 – Materials and Methods……………………………………………………………..23
2.1 – Development of Flp-In U2OS cell lines……………………………...……23
2.2 – Cell culture, protein induction and harvest………………………...………23
2.3 – Antibodies………………………………………………………….………24
2.4 – SDS-PAGE and western Blotting …………………………………………24
2.5 – GST-CK2 mutants ……………………………………………………...…26
2.6 – In vitro kinase assays………………………………………………………27
2.6.1 Inhibition of CK2’ mutants with CX-4945 inhibitor …………..
3 – Results……………………………………………………………………………….30
3.1 – Short term recovery of activity in mutant CK2 cell lines…………….......30
3.2 – The Effect of long-term CK2 inhibition on mutant recovery and cell
morphology………………………………………………………………………………40
3.3 – The Design of CK2’ mutants to recover activity in the presence of CX4945………………………………………………………………………………………46
3.4 –The recovery of phosphorylation activity of CK2’ mutants in the presence
of CX-4945………………………………………………………………………………49
3.5 – Creation and induction of CK2’ U2OS Flp-In cell lines…………………53
4 – Discussion…………………………………………………………………………...61
4.1 – Short term recovery of activity in mutant CK2 cell lines ………………..61
iv

4.2 – The Effect of long-term CK2 inhibition on mutant recovery and cell
morphology………………………………………………………………………………64
4.3 – The Design of CK2’ mutants to recover activity in the presence of CX4945………………………………………………………………………………………66
4.4 – The recovery of phosphorylation activity of CK2’ mutants in the presence
of CX-4945………………………………………………………………………………68
4.5 – Creation and induction of CK2’ U2OS Flp-In cell lines…………………71
4.6 – Future directions…………………………………………………………...75
4.7 – General summary…………………………………………………………76
5 – Appendix……………………………………………………………………………78
6 – References …………………………………………………………………………83

v

List of Figures
Figure 1: Structure of ATP, GTP, and current inhibitors of protein kinase CK2.
……………………………………………………………………………………...….…13
Figure 2: The crystal structure of the active site of CK2. …………………….…............17
Figure 3: The amino acid alignment between CK2 catalytic subunits CK2 and
CK2’…………………………………………………………………....………………19
Figure 4: The expression level of CK2 in wild type, double mutant and triple mutant
kinase. …………….…………………………………………………………….……….31
Figure 5: The titration of CX-4945. Inhibiting CK2 in cells expressing CK2 wild type,
double mutant and triple mutant kinases ……………………………….……...………..33
Figure 6: The titration of CK2 inhibitor VIII. Inhibition of cells expressing CK2 wild
type, double mutant and triple mutant forms …….………………………..……............34
Figure 7: Measuring of the ability of CK2 mutants to overcome the inhibition of CX4945…………………………………………………………………………….………37
Figure 8: Measuring the ability of CK2a mutants to overcome the inhibition of Inhibitor
VIII ………………………………………………………………...………………….39
Figure 9: Brightfield images of U2OS Flp-In osteosarcoma cells taken at different
inhibitor concentrations and time points ……………………………………….…….41
Figure 10: Measuring the ability of CK2 mutants to overcome the inhibition of CX4945 for 1, 2 and 3 days …………………………………………………………......43
Figure 11: Comparing the ability of CK2 mutants to overcome the inhibition of CX4945 and Inhibitor VIII for 48 hours at various concentrations ………………..…..45
Figure 12: Measuring the ability of CK2α and CK2α’ mutants to overcome inhibition by
CX-4945…………….…………………………………………………………...….52
Figure 13: CK2 expression in Flp-In U2OS cell lines ……………………………..54
Figure 14: Indirect immunofluorescent detection of expressed CK2α-HA and HA-CK2α’
in Flp-In U2OS cell lines……………………………………………………….….55-56
Figure 15: The titration of CX-4945 with CK2α’-WT and CK2α’-DM kinases expressed
with tetracycline in U2OS cell lines…………………………..………………..….…58

vi

Figure 16: Measuring the expression of different CK2’ constructs with and without cotransfection of the regulatory beta subunit …………………………………….………...60
Supplemental Figure 1: Comparing expression levels of endogenous and exogenous
CK2α in Flp-In U2OS cell lines ………………………………………………………...78
Supplemental Figure 2: Measuring the expression of exogenous levels of CK2α in the
presence of inhibitor VIII ………………………………………………………………..79
Supplemental Figure 3: Brightfield images of U2OS Flp-In osteosarcoma cells taken at
different inhibitor concentrations and time points ……………………………................80

List of Tables
Table 1: The designed CK2α and CK2α’ mutant kinases with their KM values
………………………………………………………………………….………………...48
Table 2: CK2’ mutant kinases percent specific activity compared to the specific activity
of the wild type kinase ……………………………………………………..……………50
Supplemental Table 1: The concentration and specific activity calculations for each of the
mutants of CK2α and CK2α’ …………………………………………………................81

vii

Abbreviations
°C
μg
μl
μM
Akt
ATP
BCA
Bcl-2
Bid
BSA
Cdk1
Cdk2
CK2
CK2α
CK2α’
CK2β
CK2’-WT
CK2’-DM
CK2’-TM
CK2-WT
CK2-DM
CK2-TM
CO2
CML
CX-4945
ddH2O
DFG
DMAT
DMEM
DMSO
DNA
EGF
EGFR
GAM
GAR
GFP
GST
GTP
g
HA
IPTG
IQA
kDa
Ki

degrees Celsius
microgram
microliter
micromolar
protein kinase B
adenosine triphosphate
bicinchoninic acid
B-cell lymphoma 2
BH3 interacting-domain death agonist
bovine serum albumin
cyclin-dependent kinase 1
cyclin-dependent kinase 2
protein kinase CK2 (formerly casein kinase II)
CK2 alpha, catalytic subunit
CK2 alpha prime, catalytic subunit
CK2 beta, regulatory subunit
CK2’-HA
CK2’-V67A/I175A-HA
CK2’-V67A/H161E/I175A-HA
HA-CK2
HA-CK2-V66A/I174A
HA-CK2-V66A/H160D/I174A
carbon dioxide
chronic myelogenous leukemia
CK2 inhibitor (developed by Cylene Pharmaceuticals)
double distilled water
Aspartic Acid, Phenylalanine, Glycine motif
2-Dimethylamino-4,5,6,7-Tetrabromo-1H-Benzimidazole
Dulbecco’s modified eagles medium
dimethyl sulfoxide
deoxyribonucleic acid
epidermal growth factor
epidermal growth factor receptor
goat-anti-mouse antibody
goat-anti-rabbit antibody
green fluorescent protein
glutathione S-transferase
guanosine triphosphate
relative centrifugal force
epitope tag derived from human influenza hemagglutinin
isopropyl β-D-1-thiogalactopyranoside
inhibitor [[5-oxo-5,6-dihydro-indolo(1,2-a)quinazolin-7-yl]acetic acid]
kilodalton
inhibitor constant

viii

MEK
mg
ml
mM
Myc
NF-kB
nm
nM
PBS
PBST
PCR
PDB
PKA
PML
PVDF
SDS-PAGE
TBBt
TBBz
TBS
U2OS

MAPK kinase
milligram
milliliter
millimolar
c-Myc epitope tag
NF-kappaB
nanometer
nanomolar
phosphate buffered saline
phosphate buffered saline, with tween
polymerase chain reaction
Protein Data Bank
protein kinase A
promyelocytic leukemia protein
polyvinylidene difluoride
sodium dodecyl sulphate polyacrylamide gel electrophoresis
tetrabromobenzotriazole
tetrabromobenzimidazole
Tris buffered saline
human osteosarcoma cells

ix

1
1. Introduction
1.1 – Protein Kinases
Protein kinases are enzymes that catalyze the transfer of the gamma phosphoryl
group from ATP or, in some cases, GTP to the hydroxyl group of a serine, threonine or
tyrosine residue on a recipient substrate protein [1]. There are conformational differences
that exist between the active and inactive forms of substrates. These changes are often
controlled by the addition of a phosphate by protein kinases [2]. The phosphorylation of
substrate proteins can result in activation of key cellular processes including, but not
limited to, cell survival, proliferation and control over apoptosis [3].
Alterations in the natural function of protein kinases often result in a number of
different diseases, including many different malignancies [4]. The dysregulation of
protein kinases can result in over-expression or under-expression of key genes or proteins
that can lead to uncontrolled activity with oncogenic behavior. The phosphorylation of
tumor suppressor genes or oncogenic proteins is capable of regulating their activity [5].
Overactive kinases that target these key gene products can alter downstream regulation of
vital cell signaling pathways including survival, proliferation and apoptosis [6].
As a result of the ability of kinases to control cellular processes, the human
kinome has become an attractive drug target for the treatment of uncontrolled growth and
tumorigenesis [7]. The 518 kinases of the human kinome include the targets of 30% of
the inhibitors in drug development projects by pharmaceutical companies, second only to
G-coupled protein receptors as the most pharmaceutically targeted protein type in the
human body [8].
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The first successful therapy towards a protein kinase was the use of the drug
Imatinib (Gleevec). Imatinib targets the Bcr-Abl tyrosine kinase that is overactive in a
number of malignancies including chronic myelogenous leukemia (CML) [9]. Imatinib is
an ATP-competitive inhibitor that binds the inactive form of the Bcr-Abl kinase, where
the DFG motif is pointing outwards, in order to prevent its activation. This allows for a
stronger specificity of the inhibitor, as the inactive form of a kinase is less conserved
throughout evolution and thus more distinct from other kinases [10].
Imatinib induced apoptosis in cells that were reliant on Abl for growth. Studies
showed Imatinib exhibited little cytotoxicity, as the drug did not target cells that were not
Abl-dependent. The drug showed tumor regression in leukemia after 15 weeks of
treatment [11]. The success of Imatinib has provided the basis for research into the
inhibition of other kinases for the treatment of uncontrolled cell growth [12]. Protein
kinase CK2 (formerly casein kinase II) is one of the kinases that is being examined by
researchers for its role in tumorigenesis [13].
My thesis work is focusing on protein kinase CK2 that has emerging importance
in cancer research. It is overactive in a number of cancer cells and has unique features
that make its regulation interesting [14]. There is also an inhibitor of CK2, namely CX4945, that is currently in clinical trials [15].
1.2 – Protein Kinase CK2
Protein kinase CK2 differs from many kinases which are activated in response to
specific stimuli, as CK2 is a constitutively active enzyme [16]. It is a highly pleiotropic
protein serine/threonine kinase that can recognize hundreds of proteins as substrates and
is ubiquitously expressed within the cell and throughout the body as it can be detected in
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all the organs examined in a mouse embryo [17]. It is among the kinases with the most
interacting partners, many of which control cell survival and growth. CK2 recognizes a
consensus sequence that includes a Ser/Thr N-terminal to clusters of acidic residues with
a minimum recognition requirement of: S/T-X-X-D/E [18]. Recognition of a consensus
sequence of acidic residues is less common in the majority of protein kinases.
Multiple examples of CK2 dysregulation in human disease have prompted the
interest in this kinase as a therapeutic target. It has been implicated in transformation and
development of tumorigenesis by protecting the cells from apoptosis via regulation of
tumor suppressor and oncogene activity [19]. However, the precise role of CK2 in
tumorigenesis is still not completely understood.
1.2.1 The Structure of CK2
CK2 is a holoenzyme composed of two catalytic subunits (two CK2, two CK2’
or CK2 and CK2’) as well as two regulatory subunits (CK2) [16]. The kinase exists
primarily in the tetramer holoenzyme form within the cell but the catalytic units remain
active on their own without the need of the regulatory beta subunits. Crystallographic
data demonstrated more information on the composition of the holoenzyme showing that
the tetramer of the protein exists as two regulatory CK2 subunits that connect two
catalytic CK2 or CK2’ subunits. The two CK2 subunits mediate the formation of the
holoenzyme [20]. In lymphoid cell lines, CK2 is expressed in excess of the catalytic
subunits and degraded if not immediately formed into complexes. Tetrameric complexes
including two CK2 or two CK2’ show little difference in catalytic activity but the two
catalytic isoforms have shown distinct functional activity when expressed on their own
[21].
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The constitutive activity of CK2 can be explained by its unique structure. There is
a conserved DFG motif across the majority of kinases found at the N-terminus of the
activation loop. “DFG-in” conformation refers to the formation of the kinase when the
phenylalanine residue within DFG forms a hydrophobic spine by binding with one
residue on the N-terminal lobe and one residue on the C-terminal lobe [22]. The DFG-in
conformation leads to activation of the kinase. Inactivation occurs when this
phenylalanine moves out of the hydrophobic pocket to alter the interaction of asparate
and glycine within the DFG, in the process, blocking ATP binding to the active site [23].
This is sometimes referred to as the DFG-out conformation. In CK2, the phenyalanine
residue common to most kinases is replaced by tryptophan at position 176 [24]. The
presence of tryptophan allows the kinase to maintain the open active state and thus
contributes to the constitutive activation of CK2. It aids in the coordination of the
arrangement of the N and C terminal lobes for the proper positioning of the essential
residues within the catalytic site to maintain the active state of CK2 [25]. The majority of
ATP competitive inhibitors that target CK2 differ from Imatinib, which can target and
stabilize the inactive state of the Bcr-Abl fusion protein.
Another unique aspect of the structure of CK2 is its small hydrophobic active site.
Specifically, it contains two hydrophobic residues, V66 and I174, at positions that are
occupied by alanine residues in the majority of protein kinases [26]. Additionally, due to
the unique active site of CK2, it can bind both ATP and GTP, whereas most protein
kinases can only bind ATP in their active sites [27]. CK2 also has a histidine residue,
which has a flexible side chain, at position 160 that is at the entrance of the catalytic site.
The binding of ATP alters the conformation of the histidine. When ATP is bound, its
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triphosphate, protruding outside the active site, keeps the imidazole ring of histidine
turned downwards, opening the mouth of the cleft in the process. When ATP is not
bound, the imidazole ring is turned back to form an H-bond with the carbonyl oxygen of
the Arg47 residue [28].
1.2.2 The Regulation of CK2
CK2 can have an influence over the ability of CK2 to phosphorylate targets but
the catalytic subunits express similar activity towards the majority of targets regardless of
whether the regulatory beta subunit is present [29]. The exact role of CK2 is not entirely
known but two of its suggested functions are: (1) altering of the activity of the catalytic
subunits of CK2 and (2) protecting the kinase from degradation. There are a number of
mechanisms of regulation of CK2 however, there is still more research to be done to
understand how the CK2subunit contributes to the regulation and activity of the kinase
[29].
CK2 appears to be regulated by a number of distinct means of regulation rather
than one universal regulatory process for all CK2 proteins in an organism [30]. The
regulation of CK2 is a result of its subcellular localization as well as its interaction with
binding partners within the cell. The interaction partners of CK2 can coordinate the
cellular location as well as its interactions with other proteins in the cell [31].
There has also been some evidence of tissue specific expression and regulation of
CK2. Several studies using rats found that CK2 has the highest expression in the brain
and testis and that CK2/’ subunits were not expressed at the same level within
different tissues. Specifically, CK2 was expressed at higher levels than CK2’ in the
spleen, liver and lung [32, 33]. CK2 expression has also varied within neuron cells within
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brain disorders such as Parkinson’s disease and metabolic disorders like diabetes [34].
Overall, this contributes to the mounting evidence that tissue specific expression is a
determining factor in the regulation of CK2.
CK2 has also been known to participate in hierarchical phosphorylation, which is
another form of regulation. In these instances, CK2 will only phosphorylate a protein if
that protein has been previously phosphorylated by another kinase. If that kinase is not
constitutively active and has the ability to be turned off and on, than its regulation will in
turn regulate the activity of CK2 [35]. Interestingly, phosphoserine or phosphotyrosine
can be recognized as a specificity determinant within the acidic consensus sequence that
was mentioned earlier. This gives further evidence for the role CK2 can play in
hierarchical phosphorylation events.
Overall, while its activity is not controlled in the same fashion as the majority of
kinases due to its constitutive activity, there are a number of regulatory mechanisms that
the cell can use to monitor the activity of CK2. The role of the regulation and
overexpression of CK2 in diseases such as tumorigenesis and cancer is justifiably the
subject of much research.
1.3 – CK2 in cancer
1.3.1 – CK2 and tumorigenesis
Elevated activity of CK2 has been associated with aggressive tumor behavior in a
number of cancers including lung [36], head and neck [37], prostate [38], kidney [39] and
breast [40] Furthermore, overexpression of CK2 in mouse models resulted in the
transformation of T-cells and mammary gland epithelium, which led to the development
of tumorigenesis [41]. In addition, an increase in CK2 levels coupled with increased
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levels of c-Myc or Tal-1 or with decreased expression of tumor suppressor p53 resulted
in a further increase of oncogenic activity thus promoting tumorigenesis [42,43]. In
addition to the role CK2 plays in interacting with oncogenes, CK2 also protects cells
from apoptosis via interactions controlling caspase cleavage, degraded proteasome
susceptibility and the altered the activity of oncogenes as well as tumor suppressors.
1.3.2 – CK2 and tumor suppressors
Tumor suppressor genes are responsible for the slowing of cell growth, the
facilitation of DNA repair and they play a key role in apoptosis. The phosphorylation of
tumor suppressor genes can alter their activity to increase or decrease affinity to targets.
Phosphorylation also plays a role in the protection and promotion of tumor suppressor
genes from degradation [44]. CK2 interacts with PML to alter susceptibility to
proteasomal degradation [45]. The CK2 phosphorylation of tumor suppressor PTEN
stabilizes the inactive form of the protein. CK2 also phosphorylates Tp73 to deactivate it
in cell [46].
1.3.3 CK2 and Oncogenes
An oncogene is a protein that when mutated has the potential to promote cancer.
They are often expressed at elevated levels in tumor cells. Elevated CK2 levels have been
associated with the promotion of a number of gene products that control proliferation and
apoptosis [47]. While CK2 is not itself considered an oncogene, it directly targets a
number of known oncogenes including c-myc, c-myb, c-jun, B-catenin, Wnt and PI3-K
[48, 49]. Overexpression of CK2 leads to elevated levels of some of these proteins
potentially leading to protection from apoptosis and elevated cell growth levels [50].
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1.3.4 – CK2 in apoptosis
CK2 is known to phosphorylate components of the apoptotic machinery. The proapoptotic protein Bid that activates mitochondrial apoptotic machinery is targeted for
phosphorylation by CK2 to inhibit its activation [51]. CK2 also functions to stimulate the
apoptotic inhibitor survivin via beta-catenin-Tcf/Lef-mediated transcription [52]. Both
the deactivation of pro-apoptotic signals and the stimulation of apoptotic inhibitors
function by preventing caspase activation, which is normally responsible for the
execution of apoptosis. CK2 also directly phosphorylates caspases and caspase substrates
proximal to caspase cleavage site to inhibit caspase-mediated cleavage [53].
Kinase negative studies, where the transfection of mutated CK2 kinases that lack
key residues for the for the ability of CK2 to phosphorylate substrate proteins, and
chemical inhibition studies have shown that lowering the level of CK2 in cell results in
the attenuation of apoptosis. Studies performed using cells expressing mutant forms of
CK2 face the issue of endogenous CK2 present within the cell population, which can
confound the effect of the CK2 mutants [54]. To overcome this limitation, the
development of cell permeable pharmacological inhibitors of CK2 have enabled an
alternative strategy for interfering with the activity of CK2 within cells.
1.4 – The Inhibition of CK2
1.4.1 – Kinase Inhibitors
Two of the categories that kinase inhibitors can be separated into are allosteric
inhibitors and competitive inhibitors. Allosteric inhibitors target outside the active site of
the kinase but still inhibit the kinase’s activity. They usually act by binding independent
of the active site to alter the binding site so that the substrate will no longer fit, thus
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keeping the kinase in the inactive state. Competitive inhibitors face the challenge of
having to compete with the high cellular concentrations of ATP and therefore, in order to
be effective, they must be present at intracellular concentrations that significantly exceed
their in vitro determined KI values [55].
Allosteric inhibitors are generally needed at lower concentrations than
competitive inhibitors due to the fact that they do not need to outcompete the high
intracellular concentrations of ATP. Allosteric inhibitors also tend to target kinases more
specifically by binding to residues outside the active site where there is lower
conservation of residues [56]. However, allosteric inhibitors are thought to be less
effective due to lower affinity for their targets and therefore decreased inhibitor potency.
Allosteric inhibitors also often have reduced intracellular stability, difficulty with uptake
in the cell and issues with bioavailability [57].
Competitive inhibitors directly compete with the ATP substrate by mimicking the
structural properties of ATP in order to efficiently bind the active site. The high level of
conservation among kinases means there are only small differences within their ATPbinding pockets, which makes it difficult to develop selective inhibitors for one kinase
without affecting a large number of off-target kinases. However, complete selectivity is
not always necessary for a kinase inhibitor to be effective and to be accepted in clinical
trials [58]. In fact, it can sometimes be seen as a benefit of a drug to bind and affect
multiple pathways involved with diseases. This type of inhibitor requires a large library
screen of candidate compounds, which can be time consuming and expensive. Despite
this limitation, many ATP-competitive drugs are now available and are under
investigation in clinical trials.
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1.4.2 CK2 Inhibition
CK2 has emerged as a potential therapeutic target due to its anti-apoptotic role as
well as its role in many cellular processes. One competitive inhibitor of CK2, designated
CX-4945, has already entered into clinical trials. CK2 inhibitors have also been utilized
in experimental studies to test the role of CK2 within cellular processes and to identify
bona fide targets of CK2. One of the original strategies used to alter CK2 levels within
cells was to transfect kinase-inactive CK2 mutants into cells. However, the long half-life,
the cellular localization as well as the high endogenous expression of CK2 in cells limited
the effectiveness of these studies [54]. The developments of new CK2-selective inhibitors
serve as a more efficient way to study the effect of inhibiting CK2 within cells. The
chemical inhibitors can penetrate and inhibit the majority of [9, 14, 15] exogenous and
endogenous CK2 in the cells.
Non-competitive allosteric inhibitors would generally target the beta subunit or
the interaction between alpha and beta subunits [59]. The majority of currently available
CK2 inhibitors however, are ATP-competitive inhibitors that directly target the small
hydrophobic active site of CK2. Researchers were able to take advantage of the unique
binding pocket of CK2 to design inhibitors that made contacts with the unique
hydrophobic valine and isoleucine residues within the catalytic pocket of CK2. These
inhibitors are smaller than the majority of kinase inhibitors and specifically target the
V66 and I174 residues. This allows them to have fewer off target reactions with other
kinases that do not share these binding pocket properties [60]. Two of the first CK2specific inhibitors that were developed were 4,5,6,7-Tetrabromobenzotriazole (TBB) ad
4,5,6,7-Tetrabromobenzimidazole (TBBz), which are the most commonly used CK2
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inhibitors in cell studies to date [61]. However, comparing the selectivity of TBB and
TBBz across a panel of 80 kinases showed that they were not as selective as initially
believed. There was also evidence that the apoptosis seen in cancer cells was, at least in
part, due to off-target effects of the inhibitors [62]. This was illustrated using rescue
experiments and inhibitor-refractory mutants, as the mutants did not enable the cells to
recover from the apoptosis associated with TBB and TBBz. Additionally, an unbiased
chemoproteomics approach revealed a number of off-target interactions of the TBB and
TBBz inhibitors [63].

1.4.3 – CK2 Inhibitors: CX-4945 and Inhibitor VIII
There is a new orally available compound named CX-4945 that has shown the
efficiency and selectivity suitable to be accepted into stage two clinical trials for the
treatment of blood-based cancers [64]. The compound was synthesized from molecule: 4oxo-4,5- dihydrothieno [3,2-c] quinoline-7-carboxylic acid by making a number of
substitutions to incorporate alkyl chains bearing aniline moieties and replacing the
existing thiopene ring with a pyridine ring [65]. To examine the selectivity of the
compound, it was tested with in vitro kinase assays against a panel of 235 other kinases
where it showed great specificity for CK2. In addition to showing strong specificity for
the kinase, it was also more potent than any of the existing CK2 inhibitors. CX-4945 has
proven to be well tolerated and possesses anti-tumor activity within mouse models. In a
study using PC3 prostate cancer xenograft mice models, CX-4945 exhibited anti-tumor
activity when delivered orally twice a day over a 35-day period. Various CX-4945
concentrations showed a linear regression in tumor growth when compared to the vehicle.
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The mice also tolerated the drug by showing no significant weight loss over the 35-day
period. Finally, when the inhibitor was tested with PC3 prostate carcinoma cells, it
showed anti-proliferation activity by inducing cell cycle arrest and initiating apoptosis
[66].
Another compound was identified as a potential CK2 inhibitor from a virtual
screen using a library of approximately three million compounds. The compound 2phenyl-1,3,4-thiadizole was found and later optimized to make 4-(thiazol-5-yl)benzoic
acid derivative, which was later named CK2 Inhibitor VIII. The improved potency of the
drug was designed with multiple favorable interactions with CK2 binding pocket. It
showed a very high level of specificity when screened against a panel of 70 kinases, only
having a minor effect on two kinases distinct from the CK2 catalytic subunits [67]. It also
showed heightened inhibitory effects in multiple cancer cell lines. While CX-4945 had
the highest level of potency of any CK2 inhibitor tested to date [67], Inhibitor VIII had a
greater efficacy on the cancer cells than did CX-4945 in terms of anti-proliferative
effects on cell lines and reducing tumor size in mice models. More tests are continuing to
be done to test and optimize the inhibitor with different cancer cells and tumor xenografts
[67]. As more CK2-specific inhibitors come through the experimental pipeline and
eventually pass to clinical trials, there is a growing need for the development of
experimental strategies to test these inhibitors. Figure 1 displays the structure of two of
the CK2-specific inhibitors which are the focus of this thesis and compares them to the
structures of two CK2 substrates, ATP and GTP.
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Figure 1. Structure of ATP, GTP, and current inhibitors of protein kinase CK2.
Chemical structures of ATP, GTP, and characterized inhibitors, CX-4945 and Inhibitor
VIII, of protein kinase CK2. Previously reported IC50 values have also been included.
[28, 65, 67]
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1.5 – CK2-Inhibitor refractory mutants
There have been a number of advances in devising strategies to test and identify
bona fide CK2 targets. In order to fall under the category of a bona fide CK2 target, the
target must meet two criteria: (1) the phosphorylation event must occur in vivo, and (2)
the phosphorylation event must change with CK2 activity [68]. The use of CK2 inhibitors
has been effective at investigating the alteration of CK2 activity in cell but there exists
the potential that the off-target drug effects are responsible for the altered level of
phosphorylation [63]. In order to address the potential lack of specificity of the kinase
being tested, we have produced inhibitor-refractory mutants of CK2 and CK2’. These
mutant kinases provide new validation tools for CK2-specific targets as they could
provide evidence that the change in phosphorylation is due to inhibition of CK2 and not
an off target [69].
Inhibitor-refractory mutants were developed by examining the crystal structure of
CK2 and identifying specific hydrophobic residues within its ATP binding pocket. The
mutations took advantage of the unique binding properties of CK2 by mutating the
hydrophobic residues, V66 and I174, in the active site to smaller and less hydrophobic
alanine residues [62]. The mutant CK2 kinases can still bind ATP through a network of
interactions similar to other kinases. This allows for maintained catalytic activity while
resisting the effects of the inhibitors.
The goal of the inhibitor refractory mutant studies was to find a concentration of
inhibitor where the wild type CK2 will be inhibited entirely but the mutant will maintain
activity. This was tested with in vitro radioactive kinase assays and with live cell culture
with the use of antibodies specific for previous established bona fide CK2 substrates [18].
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The inhibitor refractory mutants can ultimately be used to distinguish isoform specific
phosphorylation events in the cells.
Previous studies have taken advantage of a double mutant, V66A/I174A, which
reveals some recovery of CK2 activity in the presence of CX-4945 in vitro [70]. Another
study used this double mutant in cells with various concentrations of TBB inhibitor to
recover the activity toward a synthetic peptide [71]. We sought to create a mutant that
would achieve a higher recovery of activity than the previously established double mutant
and that would achieve effective recovery in live cell culture studies.
Previous studies have shown the importance of the His160 residue in binding
CX-4945. When CX-4945 binds the active site of CK2 it flips the imidazole of His160
residue downward to open up the cleft, thus locking in the inhibitor, making it more
difficult for the inhibitor to reversibly bind the target. The flexibility of the residue is
adjustable based on which inhibitor is bound [28].
Mutating the His160 (CK2) / 161 (CK2’) residues into Asp/Glu residues,
which lack imidazole ring that normally allow for stronger binding of the inhibitor, would
alleviate the ability of CK2 to lock in CX-4945 at this position. Additionally, the Asp/Glu
residues have a negative charge in place of the positive charge of the His residue,
allowing for repulsion from the original binding capabilities of the His residue.
CK2 has His115 while CK2’ has a corresponding Tyr116 (with a one amino
acid shift forward). Mutating the Tyr116 in CK2’ to a His residue would mimic the
sequence of CK2. The Tyr116 residue can also be mutated to a Lys residue, which has
the same charge as the His residue but lacks the imidazole ring, to investigate if the
charge or the imidazole ring at position 116 in CK2’ is necessary for binding the
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inhibitor. We investigated if these alterations would change the activity or the recovery
capacity of the kinase in the presence of inhibitors. The creation of inhibitor refractory
mutants for both the CK2 and CK2’ catalytic subunits could provide a tool to
investigate their independent functional roles within the cell more closely. Figure 2
shows the active site of CK2 and CK2’ with the residues of importance highlighted in
different colours.
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Figure 2. The crystal structure of the active site of CK2. The residues mutated in the
previously established double mutant kinase are highlighted in pink. The newly mutated
residue, His160, is shown in orange, residues H115/Y116 are highlighted in red and CX4945 is shown in cyan. A) PDB ID: 3E3B. The active site with corresponding mutations
in CK2’. B) PDB ID: 1NA7. The active site of CK2. C) PDB ID: 3PE1. The active
site of CK2 with CX-4945 inhibitor bound.
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1.6 – CK2 and CK2’
The two catalytic isoforms of CK2 are distinct genes that are located on different
chromosomes [72]. They share 90% sequence identity within the N terminal 330 amino
acids, and unrelated C-terminal tails [72]. While the majority of studies have shown the
two isoforms to have overlapping functions within the cell, there have been some
experiments that illustrate their functional specialization [73]. For example, CK2 is
phosphorylated within sites specific to its unique C-terminal domain, specifically at Thr
344, Thr 360, Ser 362 and Ser 370 by Cdk1/p34cdc2, while CK2’ is not phosphorylated
by p34cdc2 [74]. Differences have also been observed when investigating isoform-specific
binding partners of CK2 and CK2’. Specifically, that CK2 binds HSP90, Pin-1,
PP2A and CKIP-1 while CK2’ does not [73, 75 – 77]. Again, the C-terminal domain of
CK2 has an important role in binding with some of these proteins. The C-terminal
domain of CK2 has a proline rich area of phospho acceptor sites that is responsible for
binding Pin-1. It also contains a unique basic lysine-rich region that is responsible for the
binding of Hsp90 [74]. Figure 3 compares the sequences of CK2 and CK2’,
illustrating the similarity in the N-Terminal 330 amino acids.
Interestingly, pro-Caspase-3 was found to be the first CK2 substrate to be
selectively phosphorylated by CK2’ in cells. It was shown, by manipulating the
expression of the two isoforms to investigate their relationship with caspase-3, that
CK2’ had a significant preference for caspase-3 phosphorylation in cells when
compared to CK2. Phosphorylation of pro-Caspase-3 by CK2 can block its cleavage by
both caspase-8 and caspase-9 to prevent its activation [78].
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Figure 3. The amino acid alignment between CK2 catalytic subunits CK2 and
CK2’. The sequences are from Uniprot database (http://www.uniprot.org/) and aligned
using a BLAST (http://blast.ncbi.nlm.nih.gov). Stars between the two sequences indicate
identical residues on either isoform while a space indicates a mismatch between the
sequences. The sequence of CK2 is on the top line and the sequence of CK2’ is shown
on the bottom line. The final 40 amino acids on the C-terminal of each subunit is missing.

19

20
Several knockout studies have been performed in both yeast and rats to
investigate the independent roles of the two catalytic subunits. In Arabidopsis cells, loss
of CK2 results in the loss of cell polarity while loss of CK2’ results in cell cycle arrest
[79]. Temperature sensitive yeast mutants illustrated that knockout of CK2’ can be
compensated with CK2. In mouse models, CK2’ knockouts resulted in sterile mice but
a knockout of either CK2 or CK2 resulted in lethality of the organism [80]. Although
more studies continue in this area, there remains a limited understanding of the functional
specialization between the two CK2 isoforms. This functional specialization cannot
however, be explained by differences in catalytic activity, as both the protein subunits
have nearly identical catalytic sites.
Differences in tissue distribution have also been noted between the subunits.
Nuclear CK2 activity levels were measured in different rat tissues and there were some
distinctions in the activity levels between the two subunits. Western blot analysis using
antibodies specific for the CK2 subunit showed that it was highly expressed in the
brain, testes, spleen and liver while it maintained lower activity in the heart and kidney
[81]. Within this same experiment, antibodies specific for the CK2’ subunit illustrated
that it was most abundant in the brain and testes [81]. Overall, these findings suggest
different roles for the CK2 isoforms in different tissues and therefore functional
differences of the isoforms.
The development of double (V66A/I174A) and triple (V66A/I174A/H160D)
inhibitor-refractory mutants of both isoforms of CK2 provides us with tools to investigate
bona fide targets for the two isoforms and ultimately increase our knowledge of the
unique cellular functions of the proteins. Studies that compare the inhibited activity of
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CK2 and CK2’ with wild type and inhibitor-refractory mutants can be analyzed via
proteomics to find isoform-specific CK2 targets. The identification of these targets will
lead to a better understanding the pathways that the two isoforms participate in and how
they participate in the progression of cancer.
1.7 – Objective
A number of studies both in vitro and in mammalian cells have investigated the
interaction and inhibition of the catalytic subunits of CK2. Inhibitor studies have become
a promising tool in the investigation of catalytic and regulatory subunits of CK2 in many
survival pathways. The inhibitors function by taking advantage of the unique structural
properties of the CK2 binding pocket. Specifically, inhibitors targeted the two
hydrophobic residues: V66 and I174. Inhibitor-refractory mutants of wild type CK2 have
been examined in the past to seek validation for the specificity of the inhibitors being
used.
I hypothesize that the V66A/I174A/H160D inhibitor-refractory mutant will
recover more residual CK2 activity than models that have previously been documented in
the literature. Because of this, we will be able to create tools for the identification of bona
fide CK2 targets and the study of CK2 inhibitors unlike anything previously established. I
further hypothesize that the mutations previously created in CK2 in vitro, can be
replicated in CK2’ in vitro and that this will allow us to develop stable cell lines with
CK2’. These new cell lines can be used to compare the efficacy of inhibitors and
identification of subunit-specific targets of CK2.
The objective of this thesis is to find conditions for the recovery of residual CK2
activity in the presence of inhibitor in mutant cell populations. When these conditions are
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met, the objective is to test the effect of CX-4945 and inhibitor VIII on the
phosphorylation of previously established CK2-specific phosphorylation sites as well as
on the morphology of the cells. Once this is tested, the goal is to reproduce the same
system with CK2’ mutants, by first producing in vitro mutants and then testing those
same mutants in cell culture. Overall, these studies will provide a new strategy to test
inhibitors, find CK2-specific substrates and compare the functions of the two catalytic
subunits of CK2. Ultimately, this work and the work to follow will lead to a better
understanding of an essential protein, that has been proven to be involved with many
diseases and still has many questions surrounding its regulation and function.
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Materials and Methods
2.1 - Development of Flp-In U2OS cell lines
Human osteosarcoma (U2OS) cells, with the Flp-In integration site, were provided by
Dr. Karmella Haynes at Arizona State University [82]. The pcDNA5 vector (purchased
from Invitrogen) contained the integration sites required for the insertion of the gene of
interest. It also contained the Flp recombinase to enable insertion of the gene of interest
into the host U2OS cells. The Flp-In U2OS cell lines expressing HA-CK2’ (CK2’WT), HA-CK2’-V67A/I175A (CK2’-DM), HA-CK2’-V67A/H161E/I175A (CK2TM), CK2-HA (CK2’-WT), CK2-V66A/I174A-HA (CK2-DM) and CK2V66A/H160D/I174A-HA (CK2-TM) were generated following the directions from the
vendor (Invitrogen).
2.2 - Cell culture, protein induction and harvest
Briefly, cells were induced for 24 hours with 1 µg/ml tetracycline before being
treated with varying concentrations of CX-4945 and inhibitor VIII to examine the effect
of the inhibitors on the phosphorylation of known CK2 substrates. Cells were maintained
in Dulbecco’s modified Eagle’s medium (Corning) with 10% fetal bovine serum
(Cansera) and 1% penicillin (100 units/ml)/streptomycin (0.1 mg/ml) (Invitrogen) within
an environment of 5% CO2 at 37C. Selection media contained 150 g/ml hygromycin B
and 15 g/ml blasticidine. Induction of the cells to express the protein of interest relied
on the addition of tetracycline. The concentration of tetracycline was titrated to find the
optimal concentration of 1 µg/ml. For induction, cells were typically grown to 70-80%
confluency, then washed with PBS and the addition of fresh media containing the
selective hygromycine and blasticidine drugs as well as the proper tetracycline
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concentration. The cells were then incubated at 5% CO2 at 37C for 24 or 48 hours when
the media was again replaced with media containing 150 μg/ml hygromycin, 15 g/ml
blasticidine, 1 µg/ml tetracycline and varying concentrations (0 nM – 30 nM) of CX4945 or inhibitor VIII for an additional 3, 4, 5, 6, 7 or 8 hours after induction.
The cells were harvested with Tris lysis buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 1% NP-40, 0.1% Deoxycholic Acid) with additional protease and phosphate
inhibitors (1 mM PMSF, 7 g/ml Pepstatin A, 20 g/ml Leupeptin, 2.9 g/ml Aprotinin,
1 M Okadaic acid, 1 M Microcystin, 5 mM NaF, 1 mM sodium orthovanadate). Cell
lysates were cleared by centrifugation at 2000 x g at 4C for 15 minutes to remove cell
debris. The lysates were stored at -20C until they were run on SDS-PAGE gels.
2.3 - Antibodies
The antibody used to measure levels of exogenous and endogenous CK2 was
referred to as CK2α/α’ (diluted 1:2000 in 3% BSA/TBST). It was raised against the last
51 residues on the C terminal tail CK2’ protein that has some similarity with residues
near the C-terminus of CK2. Phosphospecific antibodies, pIF2B (pS2) and CK2B
(pS2/3/4/8) (diluted 1:10,000 in 3% BSA/TBST), were used to assess the
phosphorylation activity of CK2 on known CK2 substrates. GAPDH antibody (diluted
1:2000 in 3% BSA/PBST) was used to indicate the equal amount of protein that was
loaded on the gel. The biotinylated 3F10 antibody directed against the HA epitope
(diluted in 1:500 3%BSA/PBST) was used to detect the expression of the HA-tagged
exogenous proteins. (Roche). The goat-anti-rabbit (GAR), goat-anti-mouse (GAM)
(diluted 1:10,000 in 1% BSA/TBST) and streptavidin (SAV) (diluted 1:10,000 in 1%
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BSA/PBST) secondary antibodies (LiCor) were conjugated to fluorophores that could be
detected at 680 nm or 800 nm when scanned on the LiCor Odyssey.
2.4 - SDS-PAGE and Western Blotting
BCA protein assays (Pierce) were used to determine the protein concentration.
Samples (10 g of protein) were prepared for separation via SDS-PAGE gel first by
adding an equivalent volume of 2x Laemmli sample buffer (4% SDS, 20% glycerol, 120
mM Tris-HCl pH 6.8, 10% -mercaptoethanol) to each sample. The samples were heated
for 3 minutes at 100C and loaded onto the SDS-gel. They were subjected to
electrophoresis in SDS-PAGE buffer (192 mM glycine, 25 mM Tris-base pH 8.0, 0.1%
SDS) for 1.5 hours at 120V.
With use of a wet mini trans-blot electrophorectic transfer cell (Biorad), the
samples were transferred from the gel to a polyvinylidene difluoride membrane (Thermo
Fisher). The blot was transferred for 1 hour at 100 V in blotting buffer (20% methanol, 10
mM Tris-base pH 8.6, 767 mM glycine). The membrane was then blocked with LiCor
Blocking buffer for 1 hour followed by washing with Tris buffered saline with Tween
(TBST).
The phosphorylation state of known CK2 substrates was assessed with three
antibodies, pEEF1D, pIF2B pS2 and pCK2β pS2,pS3,pS4,pS8, which were individually
incubated with the blots for one hour each, washed three times with TBST then
incubation with the GAR800 secondary antibody. The membranes were scanned with the
Licor Odyssey scanner between each antibody. Expression of the HA-tagged proteins
was detected with biotinylated anti-HA 3F10. The membrane was washed three times
with PBST. Finally, the membrane was incubated SAV680 for 45 minutes. The primary
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antibody used on the membranes the CK2α/α’ antibody, incubated for 1 h at room
temperature, washed three times with TBST and then incubated with the GAR800
secondary antibody. In order to demonstrate equal loading the final primary antibody
used was GAPDH, washed 3 times with PBST and incubated with secondary antibody
GAM 680.
2.5 - GST-CK2 mutants
Inhibitor-refractory mutants of CK2 ’ with a point mutation at H161 or Y116
sites were generated with site-directed PCR mutagenesis. Single amino acid substitutions
were made to the wild type or double mutant. After the PCR reaction was finished,
samples were digested with Dpn1 for 30 minutes at 37C. The PCR products were mixed
with 90 L of chemically competent BL21 E. coli cells and incubated on ice for 30
minutes. The solutions were then heat shocked for 45 seconds at 42°C, mixed with SOC
media and grown up for 45 minutes before being grown on Ampicillin plates overnight.
Single colonies were picked from the LB agar ampicillin plates (100 µg/ml
ampicillin), grown up in liquid media and the plasmid DNA was isolated using a plasmid
DNA kit (Qiagen) following the manufacturer recommendations. The sequence was then
verified by the forward sequencing primer, pGEX
5’(GGGCTGGCAAGCCACGTTTTGGTG, 3’ end of GST tag). GST-CK2’, GSTCK2’ (Y116L), GST-CK2’ (H161D), GST-CK2’ (H161E), GST-CK2’
(V66A/I174A), GST-CK2’ (V66A/I174A/Y116H), GST-CK2’
(V66A/I174A/H161E), GST-CK2’ (V66A/I174A/H161D) plasmids encoding the
protein of interest that were transformed into BL21 cells were grown in 2xYT media (16g
tryptone, 10g yeast extract, 5g NaCl, 1L ddH20, pH7.0) at 37C for 9 hours until the
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optical density at 600 nm reached 0.6 Induction of protein expression was achieved with
the addition of 1 mM IPTG overnight.
Bacterial cells were harvested by centrifugation (5000 X g) in 500ml bottles for
15min at 4°C. Media was decanted from cell pellets, the supernatant was discarded and
the pellet was resuspended in 50-100ml of cold PBS cultures before centrifugation (4420
X g) for 15 minutes at 4°C. The PBS was decanted and the cell pellets were resuspended
in 15ml of cold PBS (with protease inhibitors). Cells were then run through a
homogenizer in order for them to be lysed. 10% Triton-X100 was then added to make a
final concentration of 1% to lysate. The suspension was then rotated at 4°C for 15min
and the supernatant was then cleared by centrifugation. The supernatant was mixed with
glutathione-agarose beads (Sigma) in a 10 ml gravity column and allowed to flow
through the column. The column was washed with 50 ml of PBS then the protein was
extracted using elution buffer (10 mM reduced glutathione, 50 mM Tris-HCl pH 8.0, 1
mM DTT).
The eluted fractions were then run on a 12% SDS-PAGE gel, stained with
Coomassie blue and boiled the coomassie stained gel in water in order to destain.
Fractions containing the desired protein were then dialyzed (50% glycerol, 50mM TrisHCl, pH 7.5, 200mM NaCl, 1mM EDTA, 1mM DTT) overnight and stored at -20°C. The
activity of the purified GST-CK2 was determined with a CK2 kinase assay following
established protocols as described in the following section [83].
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2.6 - In vitro kinase assays
In vitro kinase assays were performed to measure the activity of GST-CK2’
mutants. The activity assays were prepared by mixture of 4 L of 5X kinase reaction
buffer (10 mM MgCl2, 100 mM NaCl, [-32P] ATP, 100 M cold ATP, 50 mM Tris
buffer), 1 L of 100 µM RRRDDDSDDD CK2 acceptor peptide and 10 L H2O. Each of
the assays to determine the Km for ATP was performed by increasing the amount of cold
ATP in the kinase buffer while maintaining the same concentration of the substrate
peptide. The reactions were initiated by addition of each of the different mutant forms of
the CK2 kinase (4 L) (diluted 1:250 in kinase buffer). The kinases were added in 20second intervals. The samples were then incubated in a 37C water bath for 10 minutes,
after which 10 L of the kinase reaction was spotted onto P81 phosphocellulose paper at
20-second intervals that were timed with the initial addition of kinase. The
phosphocellulose paper was washed 3 times with 1% phosphoric acid and once in 95%
ethanol. The phosphocellulose papers were dried with a heat lamp for 10 minutes before
being exposed to phosphorimaging screen (Amersham Biosciences) for an hour. Finally,
the Storm phosphorimager was used to detect the level of 32P-labelled substrate bound to
the P81 paper. The 32P incorporated into the RRRDDDSDDD peptide was measured in
order to assess the activity of each kinase reaction. The samples were quantified in
comparison to standards that were spotted onto the same P81 paper scanned by the
phosphorimager screen. The specific activity of each kinase was calculated according to
the equation used in the appendix.
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2.6.1 - Inhibition of CK2’ mutants with CX-4945 inhibitor
The same in vitro kinase assays were prepared as described earlier this time with
the addition of either DMSO, 5 nM or 15 nM of CX-4945. Each inhibitor assay was
performed with 100 M ATP, the appropriate amount of inhibitor and brought to a total
volume of 16 L with the addition of H2O before the addition of the mutant or wild type
kinase. The inhibitors were added at 20-second intervals, 10 minutes prior to the addition
of the kinase solution, which was also added in 20-second intervals. Samples were
processed as described above. The level of radioactivity was measured on each spot by
the Storm phosphorimager. This corresponded to the activity of the reaction and thus the
effectiveness of the CX-4945 inhibitor on the various mutants and concentration of drug
used. From the relative intensity measured on the Storm phosphoimager, we were able to
calculate the specific activity of each of the kinases at differing drug concentrations.
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Results
3.1 – Short-term recovery of activity in mutant CK2 cell lines
Three constructs, CK2-HA (Wild type, WT), CK2-V66A/I174A-HA (double
mutant, DM) and CK2-V66A/I174A/H160D-HA (triple mutant, TM), were transfected
into tetracycline-inducible U2OS Flp-In cell lines without the addition of the regulatory
CK2β subunit. Because of the single integration site in Flp-In cells, the Flp-In system
does not allow for bidirectional transfection and therefore the regulatory subunit cannot
be transfected into the system alongside the HA-tagged CK2 kinase. Even in the absence
of exogenous CK2 β, expression of the HA-tagged CK2 was detected.
A titration experiment was performed in order to evaluate the tetracycline
concentration needed for optimal expression. This, collected by S. Fess, was found to be
1 µg/ml (supplemental Figure 1), which was subsequently used as the concentration for
all the experiments described within this section. The expression of CK2-HA, detected
using the HA-3F10 antibody for both the CK2α-DM and CK2α-TM kinases, was
consistent with the expression level of the CK2α-WT kinase. (Figure 4).
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Figure 4. The expression level of CK2-HA in CK2-WT, CK2-DM and CK2TM kinase. Cells CK2-HA DNA construct was induced in the Flp-In U2OS cells for 24
increments over the span of 120 hours with 1 µg/ml tetracycline. The CK2/’ antibody
was used to compare the level of exogenous CK2 to the endogenous CK2 an CK2’.
The GAPDH antibody was used as a loading control. Protein lysate was harvested,
blotted and incubated with HA-3F10 antibody in order to measure the expression of the
protein.
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After noting the consistently elevated expression level of the CK2-WT, CK2DM and CK2-TM kinases, the cells expressing different forms of the kinases were
treated with a titration of two different CK2-specific inhibitors. The three different cell
lines were treated with increasing concentrations (DMSO control, 15 M and 30 M) and
time points (1, 3, 4, 5, 6, 7 and 8 hours) of the CK2-specific inhibitors CX-4945 and CK2
Inhibitor VIII. (Figure 5 and 6).
The experiment measured the ability of the different mutants to phosphorylate a
known CK2 substrate in varying concentrations of CX-4945 and Inhibitor VIII. This will
indicate the importance of the residue being mutated in binding inhibitors as well as
indicate the ability of the mutant to overcome inhibitor treatment. Based on these
experiments, the optimal condition for recovery of the CK2-TM kinase, when compared
to the activity of the CK2-WT kinase, was found to be 7 hours at 30 M CX-4945. The
optimal condition for Inhibitor VIII was found to be 6 hours at 15 M CK2 Inhibitor
VIII; half of the inhibitor concentration needed with CX-4945 treatment. (Figure 5 and
6). Because both Figure 5 and Figure 6 were titration experiments attempting to find
concentrations necessary for inhibition, they were only performed once and error bars
were not included.
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Figure 5. The titration of CX-4945. Inhibiting CK2 in cells expressing CK2 in
CK2-WT, CK2-DM and CK2-TM kinase. Expression of CK2-HA was induced
in U2OS Flp-In cells for 48 hours with 1 µg/ml tetracycline, then tested with various
concentrations (0, 15, 30 M) and time points (0, 1, 3 5, 7 hours) of CX-4945. The
GAPDH antibody was used as a loading control. Protein lysate was harvested, blotted
and incubated with pIF2 antibody to measure the inhibition of phosphorylation of pIF2
with the inhibitor-refractory mutants . The bar graphs measure the residual CK2 activity
with DMSO control as 100% at 7 hours of CX-4945 treatment at a concentration of 0, 15
and 30 µM. Residual CK2 activity is measured by dividing the pIF2 signal by the
GAPDH loading control and comparing that to the level of the DMSO positive control.
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Figure 6. The titration of CK2 inhibitor VIII inhibition of cells expressing in CK2WT, CK2-DM and CK2-TM kinase. Expression of CK2-HA was induced in
U2OS Flp-In cells for 48 hours with 1 µg/ml tetracycline, then tested with increasing
concentrations of inhibitor VIII from 0 to 30 M and time points from 0 to 8 hours. The
GAPDH antibody was used as a loading control. Protein lysate was harvested, blotted
and incubated with pIF2 antibody to measure the inhibition of phosphorylation of pIF2
with the inhibitor-refractory mutants . The bar graphs measure the residual CK2 activity
with DMSO control as 100% at 6 hours of inhibitor VIII treatment at a concentration of
0, 15 and 30 µM. Residual CK2 activity is measured by dividing the pIF2 signal by the
GAPDH loading control and comparing that to the level of the DMSO positive control.
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These inhibitor concentrations and incubation times were tested in quadruplicate
and triplicate replicates respectively within a single experiment shown in figure 7 and 8.
The CK2/’ antibody showed the levels of exogenous CK2 in comparison to
endogenous CK2 and CK2’ already present in the cell population. The exogenous
level of CK2-HA, which was stably expressed in the tetracycline-inducible cells and is
shown at the 48 kDa marker, was consistently two-fold higher than that of the
endogenous CK2, which can be seen just below the exogenous CK2-HA band.
Another trend worth noting is the disappearance of the endogenous CK2’, which can be
seen just below the endogenous CK2 band, after induction of exogenous CK2 and
incubation with CX-4945 inhibitor. The HA-3F10 antibody shows the level of expression
of the induced protein. Figure 7 illustrates that all the tetracycline-induced cell lysates
were expressing a high level of exogenous CK2alpha, based on the signal near the 48
KDa band, when compared to the non-tetracycline induced negative control. (Figure 7).
Three different CK2-phosphospecific antibodies, pIF2B pS2, pEEF1D pS162 and
pCK2 pS2,3,4,8, were tested with the treated cell lysates. It can be seen in Figure 7 that
pIF2B showed the most dynamic phosphorylation change following inhibitor treatment,
thus it was the most appropriate antibody to be used to measure the activity and inhibition
of CK2 with CX-4945 and CK2 Inhibitor VIII.
Measuring the intensity from the pIF2B signal, the inhibited double mutant kinase
did not recover any activity when compared to the inhibited CK2-WT kinase. The
CK2-WT kinase displayed a relative phosphorylation signal of 15% at 7 hours of 30
M CX-4945 when compared to the uninhibited cell lysate. The CK2-DM kinase
displayed a relative phosphorylation signal of 16% under this same condition. The CK2-
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TM kinase showed 57% phosphorylation signal compared to its positive control that was
induced with tetracycline but not treated with inhibitor. This corresponded to a recovery
four-fold more than the CK2-WT and CK2-DM kinases. (Figure 7).
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Figure 7. The measure of the ability of CK2 mutants to overcome the inhibition of
CX-4945. Cells were induced for 48 hours with 1 µg/ml tetracycline, incubated with CX4945 for 7 hours at a concentration of 30 uM. The CK2/’ antibody was used to
compare the level of exogenous CK2 to the endogenous CK2 an CK2’. The GAPDH
antibody was used as a loading control. Cells were harvested, proteins are extracted via
lysis, blotted and incubated with pEE1D, pCK2 and pIF2 antibodies to measure the
inhibition of the inhibitor-refractory. A) The blots for each antibody being used. B) The
quantified values for the residual CK2 activity with DMSO control as 100% performed in
quadruplicate. T-test analysis showed a p-value of 7.8x10-4.

37

38
The higher potency of Inhibitor VIII over CX-4945 was the largest observable
difference between the two tested inhibitors in the experiments. The CK2-WT kinase
was inhibited with Inhibitor VIII at half the concentration (15 M) needed with CX-4945
(30 M). The inhibitor-refractory mutants were treated with the same concentration of
inhibitor as the CK2-WT kinases. Other than that, cells inhibited with CK2 inhibitor
VIII showed many of the same trends, specifically how well the CK2-DM and CK2TM cell populations recovered activity compared to the CK2-WT. CK2-WT kinase
displayed a relative activity of 17% to the uninhibited kinase at 6 hours of 15 M CK2
inhibitor VIII. The CK2-DM kinase displayed a 16% activity under this same metric.
The CK2-TM kinase showed 83% activity compared to the uninhibited positive control,
a recovery of five-fold more than the CK2-WT and CK2-DM cell populations. While
the overall trends between the two inhibitors were quite similar, the CK2-TM cell line
showed a higher recovery with CK2 inhibitor VIII than the same cell line with CX-4945.
Inhibitor VIII showed the exact same trends as CX-4945 concerning the CK2
antibodies used (Figure 8) and the levels of exogenous compared to endogenous CK2
expressed in the cell when induced (supplemental Figure 2).
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Figure 8. Measuring the ability of CK2a mutants to overcome the inhibition of
Inhibitor VIII. Cells were induced for 48 hours with 1000 µg/ml tetracycline and then
incubated with inhibitor 8 for 6 hours at a concentration of 15 uM. The CK2/’
antibody was used to compare the level of exogenous CK2 to the endogenous CK2 an
CK2’. The GAPDH antibody was used as a loading control. Cells were harvested,
lysed, blotted and incubated with pEE1D, pCK2 and pIF2 antibodies to measure the
inhibition of the inhibitor-refractory. A) The blots for each antibody being used. B) The
quantified values for residual CK2 activity with DMSO as 100%, performed in triplicate.
T-test analysis showed a p-value of 3.18x10-2.
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3.2 – The effect of long-term CK2 inhibition on mutant recovery and cell
morphology
After testing the short-term inhibition of the different mutants of CK2 within a
cell population, we became interested in how the inhibitors would alter the activity of the
kinases after multiple days of treatment and whether lowering the activity level of the
CK2-HA protein for prolonged periods of time would alter the morphology of the cells.
The expression of CK2-HA proteins were induced with 1 µg/ml tetracycline for 48
hours and inhibited for 24, 48 and 72 hours with 0 10 and 20 M of CX-4945. The
morphology of the cells began to change after one day. By the second day, many of the
cells were floating in the media on the plate (supplemental Figure 3), indicating that they
had lost the ability to adhere to the plates, likely due to the inhibitor causing cell death.
By the third day, the majority of the cells were floating and likely dead. In order to test
the effect of the inhibitor on all the cells, we needed to harvest both the living cells still
adhering to the plate as well as the cells floating in the media. (Figure 9).
Because we saw little to no recovery of the ability of CK2 to phosphorylate pIF2
with the CK2-DM kinase when compared to the CK2-WT protein and the CK2-TM
kinase had recovered a significant amount, we moved forward without the CK2-DM
cells. All of the rest of the experiments on the CK2 U2OS cell lines were focused on
comparing the CK2-WT and CK2-TM kinases.
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Figure 9. Brightfield images of U2OS Flp-In osteosarcoma cells taken at different
inhibitor concentrations and time points. Cells were induced with tetracycline for 48
hours before being inhibited with CX-4945 for 3 days (72 hours). Pictures of the cells
were taken at 10x magnification with inhibitor concentrations of DMSO control, 10 M
and 20 M CX-4945.
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After 24 hours, the CK2-WT cells demonstrated a consistent decrease in pIF2B
phosphorylation with increasing inhibitor concentration. However, there was not a linear
decrease in pIF2B signal from hour 24 to 72, as the pIF2B levels did not show a
significant change between hour 24, 48 and 72 (p-value = 0.37). Figure 10 shows that the
activity of the CK2-WT was 100%, 50% and 19% for DMSO, 10 M and 20 M CX4945 treated cells, respectively, after day one. There was no significant change in the
activity between hours 48 and 72 as there was only a 15% decrease in activity to 100%,
42% and 16% for DMSO, 10 M and 20 M CX-4945 treated cells (p-value = 0.71). The
CK2-TM kinase displayed no significant decrease in pIF2B activity at any of the
concentrations or time points tested, the p-value for the DMSO treatment compared to the
72 hour, 20 M CX-4945 treatment was equal to 0.16. However, there was a significant
increase in the pIF2 signal between the inhibitor-refractory CK2-TM and the CK2WT kinase (p-value 6.2x10-3). This illustrates that the CK2-TM kinase can maintain
CK2 activity for at least 72 hours in the presence of 20 M of CX-4945. (Figure 10).
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Figure 10. Measuring the ability of CK2 mutants to overcome the inhibition of
CX-4945 for 1, 2 and 3 days. Cells were induced for 48 hours with 1 µg/ml tetracycline
and then incubated with CX-4945 for 24, 48 and 72 hours at a concentration of 0, 10 and
20 µM. The CK2/’ antibody was used to compare the level of exogenous CK2 to the
endogenous CK2 an CK2’. The GAPDH antibody was used as a loading control. Both
live and floating cells were harvested and immune-blotted with pIF2 to measure the
cellular CK2 activity. A) The immune-blots with the indicated antibodies are showing
inhibition of CK2 activity when CK2α-HA (WT), B) or CK2α-HA V66A/I174A/H160D
(TM) are overexpressed. C) The quantified values for the calculated residual CK2
activity with DMSO as 100%, performed in triplicate. T-test analysis showed a p-value
comparing the CK2α-WT to CK2α-TM inhibition at 24 hours 20 µM CX-4945 treatment
of 6.2x10-3.
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The cells were then tested at 0 µM, 10 µM and 20 µM concentrations of CX-4945
and 0 µM, 10 µM and 20 µM concentrations of Inhibitor VIII for 48 hours. The
differences in the efficacy of inhibition are less pronounced at longer inhibition periods.
Inhibitor VIII is a more effective inhibitor than CX-4945 in the CK2-WT kinase,
illustrated by the two-fold higher pIF2 signal of the CK2-WT protein with 10 µM CX4945 compared to that of the CK2-WT with 10 µM Inhibitor VIII. There was no
quantifiable difference between the recoveries of CK2 Inhibitor VIII compared to CX4945 in the CK2-TM cell line. (Figure 11). This experiment was performed only one
time and thus error bars could not be included.
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Figure 11. Comparing the ability of CK2 mutants to overcome the inhibition of
CX-4945 and Inhibitor VIII for 48 hours at various concentrations. Cells were
induced for 48 hours with 1 µg/ml tetracycline and subsequently incubated with CX-4945
or with Inhibitor VIII for 48 hours at a concentration of 0, 10 and 20 uM. The CK2/’
antibody was used to compare the level of exogenous CK2 to the endogenous CK2 an
CK2’. The GAPDH antibody was used as a loading control. Both live and floating cells
were harvested to show the inhibitor-refractory mutants inhibition. A) Immune-blots with
the indicated antibodies are shown. B) The quantified values for the residual CK2 activity
with DMSO as 100%, performed in triplicate.
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3.3 - The design of CK2’ mutants to recover activity in the presence of CX-4945
After optimizing conditions for CK2 recovery in cell line models, the next step
was to design and test mutants for the CK2’ catalytic subunit. A number of mutations
were investigated in vitro in order to identify the mutations with the highest recovery of
CK2’ activity in response to CX-4945 treatment. This mutant kinase would eventually
be transfected into Flp-In U2OS cell lines to generate CK2’ stable cell lines. The goal
of the mutant proteins was to recover CK2α’ activity in the presence of inhibitors. Many
of the same mutations that were used in the CK2 cell lines were designed in CK2’
constructs keeping in mind the one amino acid shift difference in numbering between
CK2α vs. CK2α’.
The mutations were tested first in vitro and then in cells in order to make
comparisons between the two CK2 subunits. Two new residues, Y116 and H161, were
mutated in addition to previously established V67A/I175A mutations that were tested
several times in the literature. In total, 9 different kinases – 7 novel mutations - were
designed (Table 1). The goal was to design a new form of the mutant kinase that could
recover more residual CK2 activity than in the previously studied mutants. All of the
results from the recovery of the new mutant forms of CK2’ were then compared to
previous lab results with CK2 in vitro. (Figure 12)
The new mutations were examined to determine if the altered residues influenced
the CK2’ activity in vitro without any inhibitor present. We examined whether the
mutated kinases could still transfer ATP to a synthetic peptide RRRDDDSDDD, which is
an established synthetic peptide tested in previous in vitro studies [83]. The kinases were
then incubated with increasing amounts of ATP to measure in vitro KM values. It can be
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seen in supplemental table 1, that the mutant CK2’ kinases had a similar specific
activity value to the wild type CK2’-GST kinase and also had KM values of ATP similar
to the wild type of 12 μM (Table 1). None of the mutations eliminated activity of CK2’
in vitro suggesting that CK2’ can tolerate these mutations. It also indicates that we can
investigate the interactions of these mutant isoforms of CK2’ with the CK2 inhibitor
CX-4945.
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Table 1. The designed CK2α and CK2α’ mutant kinases with their KM values of
ATP. The point mutations made to key residues both inside and outside the active site of
CK2 are indicated. There is a one base-pair shift forward in the CK2α’ catalytic subunit.
GST-CK2α data was collected by S. Fess.
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3.4 – The recovery of phosphorylation activity of CK2’ mutants in the presence of
CX-4945
The kinases were tested with and without the CK2 inhibitor CX-4945 to
investigate the ability of the mutant to maintain phosphorylation while being treated with
inhibitor. Each mutant kinase was tested with DMSO control, 5 nM CX-4945 and 15 nM
CX-4945. The phosphate incorporation value with the DMSO control was taken to be
100% activity, while the phosphate incorporation values at each of the inhibitor
concentrations was taken as a fraction of this percentage. 5 nM concentration of inhibitor
was recorded because it was the concentration where the wild type kinase was lowered
close to 0% in comparison to the DMSO control. Many of the tested mutants showed
significant recovery at this same concentration. (Figure 12).
All of the kinases were treated with DMSO control, 5 nM and 15 nM CX-4945 to
examine how well the mutants would recover activity in comparison to the wild type
kinase. Table 2 shows this data along with the p-values for the percent specific activity of
each mutant kinase in comparison to the percent recovered residual activity of the wild
type kinase. Each mutation that was designed had an inhibition of activity that was
significantly less than the wild type kinase. (Table 2).
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Table 2. CK2’ mutant kinases percent specific activity compared to the specific
activity of the wild type kinase. The table shows percent specific activity at 5 nM and
15 nM concentration of CX-4945 treatment. The factor higher than wild type and pvalues were calculated using the percent specific activity at 5 nM for each mutant in
comparison to the wild type kinase.
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The general observable trend was that every purified kinase that incorporated the
V66A/I174A double mutation had a higher recovery than its corresponding kinase that
did not contain those two mutations. Additionally, every kinase that added an additional
mutation to either of the Y116 or H161 residues had a higher recovery than the
corresponding kinase without that mutation. Mutations to His161 recovered better than
mutations to Y116. All of the mutations made in CK2’ can be compared to similar
mutations that were made in CK2 by a previous lab member (Fess 2015). (Figure 12).
The majority of trends are similar within the CK2α and CK2α’ kinase mutants
(Figure 10). His160/His161 is consistently the most optimal residue for mutation while
mutating H115/Y116 also shows significant recovery. Overall, there are a lot of
similarities within the two kinases in terms of their mutation profile in vitro. We were
interested in seeing how these similarities translate when the live in cell model are used.
The triple mutant that showed the best recovery in vitro, CK2’-V66A/I174A/H161E,
was therefore transfected into U2OS osteosarcoma Flp-In cell lines to be compared to the
CK2 triple mutant that had previously been characterized.
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Figure 12. Measuring the ability of CK2α and CK2α’ mutants to overcome
inhibition by CX-4945. A strategy was utilized in order to assess the ability of the CK2α
and CK2α’ mutants to recover from inhibition by CX-4945. The different forms of CK2
are indicated in the legend. The experiment was performed in triplicate (n=3) and each
reaction was also assayed in triplicate. Inhibited reaction results were compared to
DMSO control. A) The residual activity of CK2α’ measured at 5 and 15 nM CX-4945.
B) The percent specific activity of CK2α measured at 10, 20, 30, 40, 50 nM CX-4945,
this data was collected by former lab member Sam R. Fess.
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3.5 - Creation and induction of CK2’ U2OS Flp-In cell lines
Three CK2’ constructs were transfected into U2OS osteosarcoma Flp-In cell
lines, HA-CK2’ (WT), HA-CK2’-V67A/I175A (DM) and HA-CK2’V67A/I175A/H161E (TM). The three cell lines were then titrated with different
tetracycline concentrations but the HA-CK2’ (WT, DM or TM) would not express at a
level comparable to the CK2-HA constructs. CK2-HA transfected cell lines have an
expression level 8 times higher than the HA-CK2’ transfected cell lines. Through a
series of transient transfections, it was discovered that the HA-CK2’ constructs required
the regulatory beta subunit in order to be expressed at a level similar to the CK2-HA
constructs. (Figure 13).
While the expression of the HA-CK2’ cell lines did not produce expression
levels as with CK2-HA without co-transfection with the regulatory beta subunit, there
was still a good level of expression of the HA-tagged CK2α’ when compared to the
negative control. (Figure 13 & 15).
The expression of exogenous HA-CK2α’ was tested by immunofluorescence
comparing HA-CK2’ to of CK2-HA in the induced cell lines. The fluorescent images
showed a similar trend, the CK2’ had a more pronounced signal than the negative
control but its signal was consistently less than the signal produced by the CK2 cells.
(Figure 14).
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Figure 13. CK2 expression in Flp-In U2OS cell lines. The CK2/’ antibody was used
to compare the level of exogenous CK2 to the endogenous CK2 an CK2’. The
GAPDH antibody was used as a loading control. Expression level of CK2-HA and HACK2’ was measured with and without the co-transfection of Myc-CK2. Equal loading
was visualized by the GAPDH antibody. A) The blots with the indicated antibodies. B)
The quantified values for the fraction of HA 3F10/GAPDH.

54

55

55

56

Figure 14. Indirect immunofluorescent detection of expressed CK2α-HA and HACK2α’ in Flp-In U2OS cell lines. Flp-In U2OS cells (expressing CK2α-HA (A) or HACK2α’ (B)) were cultured in the absence (-) or presence (+) of 1 µg/ml of tetracycline for
24 hours. The cells were then fixed and stained with a FITC-conjugated Anti-HA
monoclonal antibody. Cells were also stained with a Hoechst 33258 DAPI stain in order
to visualize cell nuclei. A phase contrast image has also been included. Fields were
imaged in the absence (-) or presence (+) of tetracycline for both cell lines (A-B) (n=2).
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With this level of expression there is potential to examine CK2’ specific effects
such as the recovery of pIF2 phosphorylation with treatment with CX-4945 and
Inhibitor VIII. The CK2α’-WT and CK2α’-DM cells expressed well but the CK2α’-TM
did not express thus recovery of pIF2 phosphorylation with CX-4945 treatment was
tested with only the CK2α’-WT and CK2α’-DM cells (Figure 15).
Similar to the CK2 cells, the CK2α’-DM kinase did not recover any activity
when compared to the CK2α’-WT kinase. Induction of the kinase with 1 µg/ml
tetracycline induction did not alter the phosphorylation level of the pIF2 antibody when
treated with 10 µM and 20 µM CX-4945. Based on the experiment shown in Figure 13,
the expression level of the HA-tag was lower than the expression seen with the CK2
cells. This could have an effect on the recovery of pIF2 signal but without the CK2α’TM cell line, it is hard to make a direct comparison between the CK2 and CK2’.
Figure 15 was a titration experiment performed to find the necessary concentrations for
inhibition of CK2’ cells, it was only performed once and error bars were not included in
the figure.
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Figure 15. The titration of CX-4945 with CK2α’-WT and CK2α’-DM kinases
expressed with tetracycline in U2OS cell lines. Cells were induced for 48 hours with 1
µg/ml tetracycline, then tested with increasing concentrations from 0 to 30 M and time
points from 0 to 8 hours. The GAPDH antibody was used as a loading control. Protein
lysate was harvested, blotted and incubated with pIF2 antibody to measure the
inhibition of the inhibitor-refractory mutants. The bar graphs measure the residual CK2
activity with DMSO control as 100%.
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HA-CK2’ was only comparable to CK2-HA expression with co-transfection of
CK2. As a result, more CK2’ constructs were tested to determine if the location of the
HA-tag would make a difference in the expression level of the protein. Four constructs,
HA- CK2’, myc- CK2’, CK2’-HA and CK2-HA were transiently transfected into
Flp-In cell lines, with and without the regulatory CK2 subunit, to determine the
expression level of the HA-tagged protein.
Figure 14 shows that the constructs myc-CK2’ and CK2’-HA constructs show
a considerably higher expression level than the HA-CK2’ construct that was previously
stably transfected into the U2OS cells. The HA-CK2’ construct was expressed when cotransfected with the regulatory beta subunit. Without the presence of CK2 there was a
very low expression level for the HA-CK2’ construct when transiently transfected with
both 20 µg and 40 µg of DNA. Both myc-CK2’ and CK2’-HA had significantly
higher level of expression.
The construct CK2-HA was used as a positive control due to its high expression
level when stably transfected into Flp-In cell lines. The CK2’-HA construct had an
expression level even higher than this positive control. EGFP was co-transfected into all
of the transiently transfected constructs to allow for monitoring of the transfection
efficiency of the cells. All of the cells were tested for their transfection efficiency before
they were harvested by via EGFP incorporation. The transfection efficiency was quite
low but was consistent for each of the cell populations, maintaining an efficiency rate of
approximately 20-25% for each of the populations tested. (Figure 16).
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Figure 16. The measure of expression of different CK2’ constructs with and
without co-transfection of the regulatory beta subunit. 20 g of DNA of each CK2’
construct was transfected into Flp-In U2OS cell lines with and without the addition of 20
g of beta subunit DNA. The cells grew with the transfected DNA for 48 hours before
being harvested, blotted and incubated with HA-3F10 antibody to measure the expression
of the different CK2 DNA constructs. A) Blots of the antibodies used. B) The quantified
values for the HA 3F10/GAPDH ratio of each construct. C) The quantified values for the
HA 3F10/GAPDH ratio of each construct co-transfected with Myc-CK2β. Both bar
graphs with range bars are taken as a percentage of the most intense peak from the HACK2α’ + β construct.
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DISCUSSION
4.1 - Short-term recovery of mutant CK2 cell lines
Rescue experiments utilizing inhibitor-refractory mutants serve as a tool to
identify bona fide kinase targets. Identifying protein substrates of specific kinases
provides information about the pathways that the kinase is involved with and about the
function of that interaction. Furthermore, inhibitor-refractory mutants can investigate the
effects of different inhibitors on previously established protein substrates [84]. Based on
data shown by a previous study within the Litchfield lab that tested the same CK2-TM
mutant in vitro that was tested in sections 3.1 and 3.2 of this thesis, I hypothesized that
inhibitor conditions could be optimized to abolish the activity of the CK2α-WT kinase
while maintaining the activity of the CK2α-TM kinase.
A previous study reported that the CK2-DM kinase had a five-fold recovery
with the TBB CK2-inhibitor [61]. Since this study was published, TBB has been shown
to lack CK2-specificity and it has been suggested that its role in apoptosis results from
off-target effects [63]. This can be explained by the fact that the previous study that
reported a five-fold recovery of CK2-DM with TBB was not performed in cellular
conditions. Instead, the cells were harvested and the inhibitor was added to the cell lysate
within a test tube.
Within our study, the CK2α-DM kinase showed no recovery at the inhibitor
concentration tested with both CX-4945 and inhibitor VIII in cellular conditions. This
provides further evidence of the difference between tests that are done in vitro and those
that are performed in cell. It also gives validation to a concern that had previously been
the subject of debate, that some studies had shown the double mutant as effective in
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recovering residual CK2 activity [61] and some did not [63]. In our study, the
concentration that inhibited both the CK2α-WT and CK2α-DM did not inhibit the CK2αTM.
No previous studies have investigated the CK2α-TM kinase in cells. Thus our
research provides an advancement in the field, as a mutant that can recover activity in a
cell model has yet to be optimized. Optimal conditions were achieved for the recovery of
the triple mutant cell line with both CX-4945 and CK2 inhibitor VIII. We found that a
concentration of 30 µM for CX-4945 and of 15 µM for Inhibitor VIII eliminated pIF2β
phosphorylation in the CK2α-WT cell line while maintaining pIF2β phosphorylation in
the CK2α-TM cell line.
Previous in vitro studies have shown that CX-4945 had a IC50 of 1 nM and CK2
inhibitor VIII had an experimental IC50 found to be 32 nM [28, 67]. The concentration
needed to inhibit the activity of the CK2α-WT cell line with CK2 inhibitor VIII was half
of that needed for CX-4945, contradicting the previously published kinetic studies. This
result is significant firstly, as it again illustrates the difference between inhibitor studies
performed in vitro and those performed in cell models. There are a number of factors that
could lead to this difference between the two models. In order for inhibitors to work
within cell line models, the drugs must be able to penetrate into the cell and function
properly under physiological conditions. Inhibitors can have different efficacies at
different pHs, inhibitors will not be able to function properly on their cellular targets if
their optimal pH does not match the pH at physiological conditions. There are also a
number of phosphatases in the cell that can deactivate the inhibitor before it can bind its
target [85]. Another difference between the two models is the potential for off-targets. In
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the controlled environment of a test tube, it is less possible for the inhibitor to bind to
anything other than the target and thus off-targets are less of an issue. Cell models are far
more trustworthy and accurate in terms of predicting the efficacy of the drug within the
human body [85, 86]. This result is also of significance as it reaffirms that CK2 inhibitor
VIII is more effective than CX-4945 in inhibiting CK2 in cell. Previous studies have
shown that inhibitor VIII does in fact slow the growth of tumors in xenograft mice
models more than CX-4945 and initiates apoptosis within PC3 prostate cancer cell lines
better than CX-4945 [67].
Earlier studies have shown pCK2 pS2, pS3, pS4, pS8 and pEEF1D pS162 to be
proteins exhibiting CK2 inhibitor-dependent decreases in phosphorylation [87, 88].
Although there is not much information in the literature, previous studies performed in
the Litchfield lab demonstrated a rapid and dynamic response of pIF2 following
treatment with CX-4945. These three antibodies – pEEF1D pS162, pCK2 pS2, pS3,
pS4, pS8 and pIF2 pS2 – were tested with the different mutant CK2 kinases with both
CX-4945 and inhibitor VIII. When treated with CX-4945 and inhibitor VIII, pIF2β
antibody showed a significant decrease in phosphorylation signal in comparison to
pCK2 and pEEF1D. An earlier study investigating the effect of phosphatases on the
signaling of different CK2 signaling substrates could explain this finding. Comparing
PTEN negative and PTEN positive cells showed varying phosphorylation of pIF2β,
indicating that the phosphatase is necessary for the lowering in signal of pIF2β. pEEF1D
and pCK2 were not affected by the change in PTEN levels [89].
Overall, the inhibitor-refractory mutants served as a tool to validate CK2 targets
and compare the efficacy of CK2-inhibitors and provided a comparison to inhibitor-
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refractory mutants that have been tested in the past. Because of the effectiveness of the
inhibitor refractory mutants when treating cells for a short period of time with the
inhibitors, we moved forward to address the issue of how inhibitors would alter the
recovery of the triple mutant kinase with longer treatment periods.

4.2 - Effects of long-term CK2 inhibition on mutant recovery and cell morphology
CX-4945 has been investigated in both the short term (under 24 hours) and long
term (24 hours and over) in previous studies [90]. Within the present study, the cells
started to lift off the plate and changed morphology after 24 and 48 hours of inhibition of
both CX-4945 and CK2 inhibitor VIII. Both the cells that remained attached to the plate
and the floating cells were harvested and tested for their CK2 expression and activity. It
was important to harvest both the attached and floating cells after multiple days of
inhibition to obtain a comprehensive analysis of what was occurring to all the cells within
the population. The CK2α-TM cell line maintained the same level of pIF2 signal despite
the altered morphology of the cells.
A possible explanation for the ability of the dying cells to maintain their pIF2β
signal is the cell’s ability to prioritize phosphorylation. It has been shown that CK2 is
involved with numerous pathways, some of which are involved with cell cycle control
and others that are involved with translation [91]. When the amount of CK2 is being
limited due to pharmaceutical inhibitors, the cell will prioritize which processes are the
most important to survival and utilize the remaining CK2 for those processes while
ignoring the less important ones [92]. The osteosarcoma cells have a doubling time of 24
hours so the lessening of the ability to phosphorylate cell cycle machinery would not be
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immediately necessary to the survival of the cell. pIF2β signaling is involved with the
control of cellular translation, which is an immediately necessary function for the cell
[93], without the proper control the cells would die much more quickly than 48 hours.
The suggestion is that the cells prioritized the phosphorylation of proteins involved with
pIF2β signaling over the phosphorylation of proteins controlling cell cycle progression,
which led to a slow death of the cells that could maintain their pIF2β signal. This is
supported by the literature in that CX-4945 has been previously proven to stop cell cycle
progression at the G to M phase [66].
Our research on the change in cell morphology is based on pictures of the cells
before and after inhibition in order to qualitatively assess cell morphology. Follow up
studies should be performed to investigate this by performing cell counting assays to
obtain a more quantitative analysis of potential cell death. PARP and caspase 3-cleavage
antibodies could also be used, to investigate autophagy and apoptosis. This would test if
apoptosis is being induced at different time points in both the long and short-term and
provide a better understanding of the effect of the inhibitors.
Phosphorylation of pIF2β was maintained in CK2α-TM kinase even after three
days of incubation with CX-4945. This illustrates the ability of the mutant to maintain
activity in the long-term and it can be used as a tool moving forward to investigate both
short and long-term binding partners of the inhibitor within the cell. CK2 inhibitor VIII
had the more potent inhibition both in the short-term and the long-term. This is more
evidence for the heightened potency of this inhibitor in comparison to what was
previously considered the most potent CK2 inhibitor available. CX-4945 has gathered far
more interest as a clinical inhibitor than CK2 inhibitor VIII and is currently going
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through clinical trials for Multiple Myeloma cancer. The current study shows novel
information on the potency of a relatively untested inhibitor. CK2 inhibitor VIII is still
being optimized to improve efficiency and selectivity, therefore there is potential for a
more potent CK2 inhibitor moving forward.
Future work within this section (4.2) would involve first testing to see if the
change in cell morphology is indeed cell death by use of cytotoxicity testing [94]. A
number of antibodies can be used to test off-targets, autophagy, apoptosis and pathway
prioritization when comparing long and short-term inhibitor treatments. While there were
some limitations to the experiments within this section 4.2 and there is still a great deal of
work to be done to confirm any of the above mentioned theories, the research
demonstrates a change in cell morphology while maintaining pIF2 phosphorylation.
4.3 - The design of CK2’ mutants to recover activity in the presence of CX-4945
In order to make an accurate comparison between the two catalytic subunits of
CK2, nearly identical experiments must be performed on both CK2α and CK2α’.
Therefore, once the conditions for CK2 were optimized for recovery in cell line models,
the next step was to design and test mutants for the CK2’ catalytic subunit that could
then also be optimized in cell lines.
Previous studies that have altered key residues within the active site of kinases
have shown their influence on catalytic activity [2]. Among the most important
experiments performed within this thesis was the investigation of the ability of the
mutants of CK2 to phosphorylate substrates in the same way as wild type kinase. The in
vitro tests with the mutants phosphorylating substrates with a specific activity similar to

66

67
wild type suggests that the alterations made did not affect the ability of the kinase to bind
ATP and phosphorylate the RRRDDDSDDD in the absence of the inhibitor.
The activity of the previously established CK2 double mutant V66A/I174A was
found to be indistinguishable from the wild type kinase in a previous study [26]. Within
our results, there was a slight decrease in activity in the CK2’ double mutant
V67A/I175A. The difference within these findings could be due to the different catalytic
subunits tested, however previous findings have shown identical activity within the
catalytic subunits when tested in vitro [95]. Furthermore, a previous Litchfield lab
member similarly found a slight decrease in the activity of CK2 when the V66A/I174A
mutations were introduced to the kinase. It is reasonable to assume that mutations to
these residues into the smaller alanine residues do alter the ability of the kinase to bind
ATP.
Overall, both our results and the results found by the previous Litchfield lab
member show only a modest decrease in activity, not significant enough to take away
from the objectives of the experiment. Furthermore, within our results, the majority of
CK2’ mutants had calculated specific activities within the same general range. For the
following steps, all of the activity for the mutants was normalized in order to test their
ability to recover residual CK2 activity in the presence of CX-4945 inhibitor.
4.4 – The recovery of phosphorylation activity of CK2’ mutants in the presence of
CX-4945
It has been well documented that CK2 and CK2’ have similar catalytic activity
when tested in vitro [95]. Studies performed by previous Litchfield lab members have
investigated the ability of point mutations, made within conserved residues in the
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catalytic site of CK2, to recover residual CK2 activity in the presence of CX-4945.
However, until now no studies have been documented that have made these same point
mutations within CK2’. Such mutations could provide a new opportunity to compare
the catalytic activity of the subunits in vitro and test whether the two truly do share the
same catalytic properties in vitro. The work in part 3.1 of this thesis identified a new
combination of amino-acid substitutions (V66A/I174A/H160D) that recovers residual
CK2 activity to a level higher than previously documented. This would be the first study
to investigate a similar combination of substitutions in CK2’.
Seven novel mutations were created in the present study have not been previously
examined for their ability to desensitize CK2’ to CX-4945. There are a number of
trends that are worth investigating further. Firstly, every kinase that incorporated the
double mutation V67A/I175A recovered more residual CK2 activity than its
corresponding single mutation to residue H161 or residue Y116. This is in line with the
literature that has shown that these two residues are important to the kinase-inhibitor
interaction [60] and provides an interesting contribution to the field as there is no
documentation that the two mutations (V67A/I175A) have ever been studied in
combination with other mutations in CK2’. The ability of the CK2α’-DM kinase to
increase residual CK2 activity is consistent when it is introduced to a wild type kinase or
a kinase with another amino-acid substitution. Additionally, any additional mutations to
Y116 or H161 also increased recovery. This is noteworthy as neither of these two
residues has previously been mutated in CK2’. It suggests that these residues are also
important to the kinase-inhibitor interaction and without those specific amino acids,
interactions between the kinase and CX-4945 that help keep the inhibitor in the active site
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would be abolished. The new mutations add to the recovery that was previously
established with the V66A/I174A mutations.
The Y116 residue in CK2’ is a histidine residue in CK2, which is one of the
few residues that is not conserved between the two catalytic subunits within the Nterminal 330 amino acids. When this residue is mutated to a histidine residue in CK2’,
there is a significant recovery of residual CK2 activity in the presence of the inhibitor.
This suggests that each of these residues is necessary for binding CX-4945 in each of the
catalytic subunits.
The H161 residue is responsible for locking in the inhibitor once it is bound, thus
when this residue is taken away, the inhibitor can become unbound much more easily
[28]. While a mutation to either residue increases the recovery of the kinase, H161D/E
mutations showed higher recovery than did Y116H/L mutations. The CK2’V66A/I174A/H161E (CK2’-TM) mutant showed the highest recovery in vitro and
because of this, it was chosen to make into stable U2OS cell lines. This combination of
amino-acid substitutions can be made into stable Flp-In U2OS cells to investigate the
difference between the two catalytic subunits within a cell model.
The similarity between the mutation profiles of CK2 and CK2’ shows the
importance of the residues for both isoforms of CK2. This is in line with the literature
[72], although it is the first time anyone has investigated the differences within inhibitorrefractory mutants between the two catalytic isoforms, studies have shown that the two
subunits have shown similar properties in vitro. The similarity of their functions in vitro
is largely due to the 90% sequence identity within the N-terminal 330 amino acids [72].
The two isoforms also have very similar catalytic sites, which may provide another
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explanation for their similar activity in vitro. The analysis of both CK2 and CK2’
showed that H160/H161 was the most important residue tested in the interaction with
CX-4945. It gave further evidence that CK2’-V66A/I174A/H161E was the optimal
kinase to be transfected into cell culture.
There is concern that none of the mutations recovered residual CK2 activity to the
level of the DMSO control. Additional amino-acid substitutions can be made, to other
conserved CK2’ residues that are necessary for inhibitor binding, to address this
concern. Despite the limitations, the trends found in the in vitro investigation of CK2’
proved to be similar to a previous study performed in the Litchfield lab and provided us
with the optimal combination of amino acid substitutions that can be used as a platform
to investigate the role of CK2’ in cells. These cell lines will be compared to the studies
performed in sections 3.1 and 3.2 of this thesis.
4.5 - The creation and induction of CK2’ U2OS cell lines
Previous studies have shown that CK2 and CK2’ can be expressed at similar
levels in cells after being transfected. More specifically, CK2’ with an N-terminal HA
tag has expressed at the same level as or even higher than CK2 with N-terminal or Cterminal HA tag [96]. Within the present study, Flp-In TRex U2OS cell lines were
created via transfection with CK2α’-WT, CK2α’-DM and CK2α’-TM DNA that were
tagged with the HA epitope on the N-terminal. However, all of the previous studies made
use of co-transfection with CK2 and our study was transfected with the catalytic subunit
only. This test is of significance as it is investigating whether there is any difference
between CK2’ constructs that are co-transfected with the regulatory CK2 and
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constructs that are not co-transfected with CK2. It also tests if there is any difference
between transfections with CK2 and CK2’ constructs.
The lack of robust expression of HA-CK2’ comparable to CK2-HA was
somewhat surprising, possibly illustrating the importance of the regulatory CK2 subunit
for optimal expression of HA-CK2a’ or differences in the behaviour of CK2a and CK2a’
[72]. Seemingly, CK2-HA can be expressed at a high level without the need for the
regulatory CK2 subunit while HA-CK2’ is expressed at far lower level in the absence
of the regulatory CK2 subunit. To follow this up, we performed a transient transfection
with CK2 into cell populations of both CK2-HA and HA-CK2’. There was a
substantial increase in expression when CK2 was transiently transfected into the cells
with the N-terminal HA tagged CK2’ protein but little change in expression when
transiently transfected into the CK2-HA. It has been shown that CK2 is able to alter
substrate specificity of the catalytic subunits as well as protect the subunits from
degradation [29]. Thus it is possible that in addition to stabilizing the HA-CK2’ protein,
the CK2 could also change its interacting partners, which could lead to increased
expression.
The expression level of the HA-CK2’ co-transfected with CK2 when compared
to CK2-HA was of a similar intensity despite its appearance on the blot. It has been
proven that, during cell cycle, CK2 is phosphorylated at multiple sites on its unique Cterminal tail by the mitotic cyclin dependent kinase, Cdk1. Because CK2’ does not
share this same C-terminal tail, it is not phosphorylated at all by Cdk1 [97]. The addition
of 4 phosphate groups on the phosphorylation sites is responsible for the multiple
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banding seen in the HA blot. This explains why CK2-HA has a larger dark banding
pattern when compared to HA-CK2’ co-transfected with CK2β.The multiple banding
pattern does not necessarily imply a higher expression level of the CK2-HA tagged
protein.
While expression of the HA-CK2’ was lower than the CK2-HA cells, there
was still some level of expression of the HA-CK2’ cells when compared to the negative
control. This was further exemplified within immunofluorescence studies. Because of the
increase in expression with tetracycline induction, we performed a recovery experiment
with the HA-CK2’ cells with similar conditions to the recovery conditions tested with
the CK2-HA cells.
Of the three cell line that were made with HA-CK2’ constructs, only the CK2α’WT and CK2α’-DM were expressing, while CK2α’-TM was not. This may suggest that
the HA-CK2α’-TM construct was not viable in cells. Thus the recovery experiment tested
only the CK2α’-DM and CK2α’-WT kinase. It was shown within section 3.1 of this
thesis that the CK2α-DM kinase was not recovering with the CK2-HA cell lines. While
some previous studies have seen recovery with this mutation [61], it was mentioned in
section 4.1 that our research goes against the theory that the CK2α-DM kinase recovers
residual CK2 activity in cell. Within our research, there was also no recovery seen with
the CK2’-DM when compared to the CK2α’-WT kinase at any of the inhibitor
concentrations or time periods tested. This is in line with what we have previously seen
with the CK2-HA cells and it provides another example of this double mutant kinase
not functioning in cell for CK2α or CK2α’. This experiment was limited due to the lack
of expression in the CK2α’-TM kinase with CK2’ cells. Another limitation was the lack
72

73
of comparable expression between the two catalytic subunits, as a result, it was difficult
to make accurate comparisons between the two. The next step, in attempt to negate these
two limitations, was to test other CK2’ constructs in order to obtain similar levels of
expression across the two catalytic subunits of CK2.
In prior studies in the Litchfield lab, CK2’ constructs were tested with the HA
on both the N and C-terminal tag. In these experiments, the HA tag had a high level of
expression on either terminal tail when co-transfected with CK2 [96]. In a separate
study however, CK2’ with a C-terminal HA tag showed a high level of expression
without the need for co-transfection with CK2 [98]. Based on this finding, we decided
to test transient transfections with multiple epitope tags on either side of the CK2’
construct. This is noteworthy for a number of reasons. Firstly, it is the first test examining
the significance of the orientation of the HA tag on the catalytic subunit of CK2’.
Secondly, it is a direct comparison with the CK2 construct. Finally, if we are able to
find a construct of CK2’ that shows high levels of expression then that construct can be
made into stable cell lines to be compared to the CK2 cells that were previously
optimized with inhibitors.
In our study, the CK2’-HA construct had a significantly higher expression level
than the previously tested HA-CK2’. There are limitations to comparing the expression
levels with transient transfections to the expression levels in stably transfected cell lines.
The limitations are mostly based on the efficiency of the transient transfection. Our study
used the measures that were available to test the transfection efficiency, however these
measures are not 100% accurate. It is difficult to compare cells with low transfection
efficiency to cells that have stably transfected the DNA of interest into their genome.
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The use of the positive control CK2-HA construct, which was also used to make
the CK2 cell lines that showed high expression levels when stably transfected in section
3.1, allowed for a proper comparison to the expression level we were hoping to achieve.
The fact that, when transiently transfected, the CK2’-HA construct has a higher
expression level than the positive control CK2-HA construct suggests that the CK2α’HA construct will have similar expression levels in stable cell lines when compared to the
CK2α-HA construct that was tested in section 3.1. The low expression levels for the
transient transfection of HA-CK2’ construct explain the low expression levels for the
stable HA-CK2α’ cell lines tested in section 3.5.
The use of EGFP to test transfection efficiency could explain the relatively low
expression of all of the constructs that were tested. 20% transfection efficiency is low and
when constructs can be stably integrated into the cell’s genome, they will be able to
express at a much higher level. It is important to note that not all of the cells showed
drastically different levels of transfection efficiency, implying that the difference in
expression levels has to do with the efficacy of the constructs rather than the
effectiveness of the transfection process.
Despite the limitations of the process, the transient transfections allowed us to
find a new construct to be stably integrated into cell lines. It is hypothesized that these
cell lines will show higher levels of expression when blotting for the HA tag and can
therefore allow for a better recovery assay than the one performed within this section.
The cells can then be tested in the same manner as the CK2 cells for a direct
comparison of the action of CX-4945 and inhibitor VIII on the two catalytic subunits.
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4.6 – Next Steps
The most important next step after this thesis is to create the stable cell lines with
the CK2α’-HA constructs that induce well with tight tetracycline regulation. Once the
cell lines are created and proper selection conditions are achieved, the same tetracycline
titration should be done to achieve expression comparable to the alpha cell lines. The
cells can be tested with the CX-4945 and CK2 inhibitor VIII to find optimal recovery
conditions using the same method as performed with the CK2 cell lines in section 3.1.
The long-term treatment of CK2 overexpressed cells with CK2 inhibitors showed
some very interesting trends but also raised many questions as to how cells could be
changing morphology while maintaining their pIF2 signal. We have been able to
suggest possible explanations as to why this occurred but the suggestions should be
tested. Inhibited cells should be investigated with antibodies that indicate cells are going
through apoptosis, such as PARP or caspase-cleavage antibodies, to examine at which
point the cells are going through apoptosis and whether or not the inhibitor-refractory
cells are able to recover from cell death. A series of other experiments can investigate
whether the inhibitors are producing off-target effects within the cells.
There was a great extent of investigation in this study into the importance of
orientation of epitope tags in kinase expression. While we were able to determine which
orientation and which tags were optimal for expression, further studies should be done to
investigate why the orientation has such a large effect. Immunoprecipitation experiments
could be performed with epitope tags on either side of the kinase to investigate whether
the orientation affects the ability of CK2 to bind specific binding partners.
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4.7 - Conclusion
We were able to optimize mutant CK2 cell lines in terms of recovery with
multiple potent CK2-specific inhibitors. CK2 inhibitor VIII and CX-4945 were compared
and characterized in terms of their potency, recovery with inhibitory-refractory mutants
and long-term toxicity. The inhibitor-refractory mutants were demonstrated to be
important tools for the investigation of inhibitor specificity and could prove to be helpful
in the identification of bona fide subunit-specific CK2 targets with the use of proteomics.
An interesting trend was noted when osteosarcoma cells were inhibited for multiple days.
Cells were changing morphology on the plates but the inhibitor refractory cells were still
able to maintain their recovery. This not only shows a remarkable ability of this mutant
kinase to recover activity within the cell, it also opens a series of questions on the
specificity and efficacy of the inhibitors under investigation. While possible explanations
for the phenomenon were suggested, further work needs to be done in order to fully
understand the role of CK2 within the change in cell morphology that was observed.
Seven novel mutations made to CK2α’, similar to mutations made to CK2α in a previous
study within the Litchfield lab, were investigated in vitro. The similarity in the residual
CK2 activity shown in the study of both CK2α and CK2α’ suggests similarity between
the activity of CK2 and CK2’ in vitro. It was shown that in cell assays differed greatly
from the in vitro assays, in terms of inhibitor potency and the difference between the two
catalytic subunits. The orientation of HA tag was of critical importance within the CK2’
cell line, and new constructs have been made and tested to be transfected into stable cells
lines. Those will be tested in future studies. The work done within this study will provide
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a useful tool for the investigation of isoform specific targets of a protein kinase whose
role in tumorigenesis has been largely unknown up to this point.
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5 – Appendix

Supplemental Figure 1. Comparing expression levels of endogenous and exogenous
CK2α in Flp-In U2OS cell lines. Flp-In U2OS cell (expressing CK2α-HA or CK2α
(V66A/H160D/I174A)-HA were cultured in the presence of 1mg/ml of tetracycline and
harvested at increasing time intervals (0-48 hours). Protein expression was assessed using
Western blots and a CK2α/α’ antibody capable of detecting endogenous and exogenous
CK2α species simultaneously. A) Different tetracycline concentrations tested with the
CK2α-WT kinase and B) CK2α-TM kinase. C) Different time points tested with the
CK2α-WT kinase and D) CK2α-TM kinase.
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Supplemental Figure 2. Measuring the expression of exogenous levels of CK2α in
the presence of inhibitor VIII. Cells were induced for 48 hours with 1000 ng/ml
tetracyclin and then incubated with inhibitor VIII for 6 hours at a concentration of 15 uM.
Cells were harvested, lysed, blotted and incubated with CK2α/α’ antibody to measure the
expression of the exogenous protein in comparison to the endogenous levels of CK2α and
CK2α’.
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Supplemental Figure 3. Brightfield images of U2OS Flp-In osteosarcoma cells taken
at different inhibitor concentrations. Cells were induced with tetracycline for 48 hours
before being treated with CX-4945 for 2 days (48 hours). Pictures of the cells were taken
at 20x magnification with inhibitor conditions of DMSO control, 10 M and 20 M CX4945.
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Supplemental Table 1. The concentration and specific activity for each of the
mutants of CK2α and CK2α’.

81

82
Sample calculation
Calculating specific activity (GST-CK2α)
All reactions were performed in triplicate and an average was taken, this represents a
single reaction.
[GST-CK2α’]= 1.25 mg/mL
2 μL of GST-CK2α (1.25 μg/μL) was initially diluted into 250 μL of CK2 dilution buffer
Therefore, (2 μL)* (1.25 μg/μL)= 2.5 μg of GST-CK2α
Next, 4 μL of the 250 μL sample was taken in order to start the kinase reaction
Therefore, (2.5 μg)*(4 μL/ 250 μL)= 0.04 μg
The reaction proceeded for 10 minutes
10 μL of the total kinase reaction (20 μL final volume) was then spotted onto P81 paper
Therefore, (0.04 μg)/2 = 0.02 μg of GST-CK2α
The 10-minute reaction (GST-CK2α phosphorylating a RRRDDDSDDD peptide) yielded
a count (CPM) of 17000000, and the spotted standards yielded a CPM of 53000000
Therefore, to calculate the CPM/pMol of ATP in the standard – (53000000 CPM) /(10 μL
spot * 100 μM ATP * 5 for the dilution)= 11000 CPM/pMol
Therefore, to calculate the specific activity of GST-CK2α:
(17000000 CPM) / (11000 CPM/pMol)= 1600 pMol of ATP incorporated onto the
RRRDDDSDDD peptide
(1600 pMol) / (10 minutes)= 160 pMol/min
(160 pMol/min) / (0.00002 mg) = 780000pMol/min/mg of GST-CK2α
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